REGULATION OF MELANOGENESIS IN B16 MOUSE MELANOMA CELLS BY

PROTEIN KINASE C (PKC)

DISSERTATION

Submitted to the Graduate School

of

Marshall University

In Partial Fulfillment of the Requirements for
The Degree of Doctor of Philosophy
by

Harish Mahalingam
Huntington
West Virginia

1996

1

I

©COPYRIGHT 1996

1

APPROVAL OF EXAMINING COMMITTEE

Susan Jackman, Ph. D.

Michael Moore, Ph. D.

u XI

S'""

Donald Primerano, Ph.D.

Vernon Reichenbecher, Ph.D.

Date

Richard Niles, Ph.D., Chair

Accepted by Graduate School

Date

Leonard J

Dean

1

Dedicated
to
MY GRANDPARENTS

Shri. & Smt. M. P. Kuppuswami Iyer

ACKNOWLEDGEMENTS

My sincere thanks are due to my advisor, Dr. Richard M. Niles, who not only gave
the environment to develop my skills, but in addition has given me an example to emulate

in my career. I wish to thank Dr. & Mrs. K. V. Raman and my parents for their unstinted
support and encouragement. They have given me direction to my meandering course of

my academic career.

The project would have been an non-starter, if not for the timely help from our
collaborators, Dr. Shigeki Shibahara and Dr. Masayoshi Tachibana. I also would like to
specially thank Ms. Faustina Fenton, Dr. Dinakar Desai and Dr. Ken-ichi Yasumoto, who

trained me in most of the techniques.

Last, but not the least, I thank my colleagues Kristy, Roger, Sejal, Steve and Gary
for “helpful” discussions.

ii

TABLE OF CONTENTS

Acknowledgements

ii

Table of Contents

iii

List of Figures

v

List of Abbreviations

viii

INTRODUCTION

1

Melanin synthesis

1

Melanocyte and Melanoma

5

Pigment Cell-specific Transcription

5

PKC and differentiation

8

Retinoids

10

Retinoids, PKC and Melanin synthesis

11

Experimental Objective

13

MATERIALS AND METHODS

15

Cell Culture

15

Treatment of cells with the phorbol esters and RA

15

Tyrosine Hydroxylase enzyme assay

16

PKC enzyme assay

17

Western blot analysis for PKCa, tyrosinase, TRP1 and TRP2

18

RNA isolation and Northern blot analysis

19

Construction effusion genes

21

Transient transfection

22

Preparation of nuclear extracts

23

Gel Mobility Shift Assay

24

iii

RESULTS

26

PART I

ROLE OF PKC IN MELANOGENESIS

26

Summary

26

A. PKC and density-dependent melanogenesis

28

B. PKC and cAMP-induced melanogenesis

48

Discussion

56

PART II

REGULATION OF MOUSE TYROSINASE PROMOTER FUNCTION

60

Summary

60

A. Transcriptional regulation

62

B. Promoter protein-DNA interactions

68

C. Cell density is a key regulator of tyrosinase expression

74

D. Identification of trans-acting factors that may play a role in complex

80

formation at the M-box region

88

Discussion
PART III
ROLE OF RA IN TYROSINASE EXPRESSION

93

Summary

93

A. Regulation of mouse tyrosinase promoter function by RA

94

B. The M-box region binds RARs

98

Discussion

104

CONCLUSION

106

REFERENCES

109

iv

1

List of Figures

Figure 1: Schematic of melanin biosynthesis pathway

3

Figure 2: Concentration and time-dependent effect of PDBu on B16 mouse

melanoma tyrosine hydroxylase activity
(A) Concentration-dependent effect

30

(B) Time-dependent effect

31

Figure 3: Effect of PDBu on the growth of B16 mouse melanoma cells.

34

Figure 4: Concentration-dependent changes induced by PDBu in B16 cells

Figure 5:

Figure 6:

Figure 7:

(A) PKC enzyme activity

36

(B) tyrosinase protein level induced by PDBu in B16 cells.

37

The effect of different phorbol derivatives in B16 cells on
(A) tyrosine hydroxylase activity

40

(B) PKCcc protein levels

41

(C) TRP-1 protein levels

42

(D) tyrosinase protein levels

43

(E) TRP-2 protein levels

44

The effect of different phorbol derivatives on mRNA level of

(A) tyrosinase

47

(B) TRP-1

47

Effect of 8-bromo cyclic AMP with or without PDBu in B16
mouse melanoma cells on

(A) tyrosine hydroxylase activity

50

(B) TRP-1 protein levels

51

(C) tyrosinase protein levels

52

(D) TRP-2 protein levels

53

v

Figure 8:

Nucleotide sequence and functional analysis of the 270 bp
region of the mouse tyrosinase promoter.

A. Schematic of the mouse tyrosinase promoter

64

B. Localization of the c/s-acting elements responsible for
transcription of the mouse tyrosinase gene.

65

C. Effect of acute and chronic PDBu treatment on reporter

gene activity in B16 cells transfected with the plasmid
pMTL1

Figure 9:

66

Effect of PDBu treatment on nuclear protein binding to a region

of the mouse tyrosinase promoter encompassing the

M-box and flanking residues
A. Schematic of the synthetic oligonucleotides wt-1, mt-1 and
mt-2 and their relative position with the mouse
70

tyrosinase promoter

B. Binding of nuclear protein complexes at the M-box region

71

C. Effect of chronic PDBu treatment and localization of regions
where the complexes may bind

72

D. Effect of chronic treatment of B16 cells with PDBu on PKCa

73

protein levels

Figure 10:

Figure 11:

Cell density-dependent changes
A. tyrosinase protein levels

77

B. PKCcc protein levels

78

C. Nuclear protein complexes at the M-box region

79

Determination of endogenous c-fos and c-jun binding to wt-1

and consensus AP-1 oligonucleotides
A. Endogenous c-fos and c-jun binding to the wt1 oligonucleotide

in control and PDBu-treated (chronic) cells

B. Endogenous c-fos binding to the AP1 oligonucleotide

vi

82
83

C. Endogenous c-fos and c-jun binding to wt1 oligonucleotide

in PDBu-treated (acute) cells
Figure 12:

Evidence that MITF is a component of complex a

Figure 13:

Effect of RA on mouse tyrosinase promoter function

84
87

A. Effect of RA treatment on reporter gene activity in B16 cells

transfected with the plasmid pMTL1

96

B. Effect of RA on nuclear protein binding and determination
of endogenous RARs binding to the M-box region

Figure 14:

97

The M-box region binds RAR
A. The DNA binding activity of RARs to the wt1 oligonucleotide

100

and p-RARE

B. wt1 binds RARs as a composite element

101

C. Mutual competition of RARa binding to p-RARE and wt1

102

oligonucleotides

vii

List of Abbreviations

PKC
RAR
RXR

protein kinase C

RARE

retinoic acid response element

mi

microphthalmia

MITF

microphthalmia-associated transcription factor

bHLH.Zip

basic helix-loop-helix, leucine zipper

PDBu

phorbol dibutyrate

DM8O
TRP1
TRP2
cDNA
mRNA
AP1
PBS
TBS

dimethyl sulfoxide

retinoic acid receptor
retinoic X receptor

tyrosinase-related protein 1

tyrosinase-related protein 2

complementary DNA
messenger RNA

associated protein-1
phosphate-buffered saline
Tris-buffered saline

INTRODUCTION

Melanin Biosynthesis

Melanogenesis is regulated by a variety of environmental and hormonal factors. In

mammals, the functional melanocytes (pigment-producing cells) are found principally
in three locations: the hair follicles, the basal cell layer of the epidermis and the eye,

including the pigmented retina, iris and choroid. They are also found in the inner ear,
the mucous membranes and the harderin gland of the mouse eye (12, 121). The

pigmentation of most mammals and birds is determined by the melanocytes of hair

and feather follicles, respectively, while humans are unusual in the importance of their
basal epidermal melanocytes. Mammalian melanocytes are capable of producing

many hues; they synthesize at least three chemically related classes of pigments (12).

These are eumelanins (usually black to brown), pheomelanins (red to yellow) and

trichochromes (red to yellow) (Greek: eu, well; melas, black; phaios, dun colored;
trichos, hair; chroma, color).
Eumelanin is a polyquinonoid pigment synthesized from tyrosine (Fig 1). The first

biosynthetic step, hydroxylation of tyrosine to dihydroxyphenylalanine (DOPA),
requires the enzyme tyrosinase, which also catalyzes the second step, oxidation of
DOPA to DOPAquinone. Thus tyrosinase is both a monophenolase (EC 1.14.18.1)
and a diphenolase (EC 1.10.3.1) (84,85). Since DOPA can spontaneously autooxidise
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and give rise to melanin, tyrosinase was thought to be the only enzyme essential to
this pathway. However, several factors have been described which influence the

production of melanin in mammals either in a positive or a negative fashion. Genetic
and biochemical studies have revealed at least two other enzymes (tyrosinase related

proteins) that function in the synthesis of mammalian eumelanin (49). The mouse
brown locus on chromosome 4 encodes a protein, tyrosinase-related protein 1 (TRP1),

having 52% amino acid identity with tyrosinase (60,132). The mouse slaty locus on
chromosome 14 encodes a protein, tyrosinase-related protein 2 (TRP2) that has about

40% amino acid identity with tyrosinase and TRP1 (143). TRP1 and TRP2 are thought
to posess dihydroxy indole carboxylic acid (DHICA) oxidase (66) and DOPAchrome

tautomerase (143) respectively, which accelerate reactions further downstream in the
melanogenesis pathway (49). The rate-limiting enzyme in melanin biosyntheis,

tyrosinase, is subject to both hormonal (82,150) and non-hormonal (80) regulation.
The gene that encodes tyrosinase has been mapped to the mouse albino locus on

chromosome 7 (79, 100, 141, 152). Both tyrosinase and TRP-1 are specifically

expressed in melanin-producing cells, such as melanocytes and retinal pigment

epithelium, which are derived from the neural crest and the optic cup of the brain,
respectively.
Melanocytes are dendritic cells that develop from melanoblasts and originate in the

neural crest (29, 30, 81, 96). They reside in the basal layer of the epidermis, the hair

follicle and the eye and are responsible for the production of pigment melanin, which

gives rise to hair, eye and skin color (133). Melanin biosynthesis occurs in specialized
2
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organelles, the melanosomes. The enzymes of melanin synthesis are contained in the
membrane-bound melanosome, produced only by melanocytes. Tyrosinase and the

two related proteins (TRP-1 and 2) have a transmembrane domain and since melanin
accumulates inside the organelle, these proteins are thought to be located on the inner
face of the

melanosomal

membrane.

However,

membraneous vesicles or

“vesciglobular bodies” observed inside melanosomes have also been suggested as
the location of melanosomal enzymes (121). Mature melanosomes are moved

outward along the dendritic processes of the melanocyte, where they are transferred
to the dividing keratinocytes of the growing hair or to basal keratinocytes of the
epidermis. The transfer seems to be directed, rather than a result of nonspecific
exocytosis and phagocytosis (44). Normal melanocytes in culture do not appear to

release melanosomes into the medium except on cell death, but will transfer them into
keratinocytes or other cells when present, apparently via dendrites (44, 77, 135). In

human skin in vivo, most melanosomes are found in the basal keratinocytes, distal to
their nuclei, in keeping with their presumed function of protecting stem-cell DNA
against ultraviolet light. In the skin, melanocytes respond to ultraviolet light by

increasing melanin production, the melanin then being transferred to the surrounding

keratinocytes as protection against UV damage (30). Excessive exposure to UV
irradiation can result in transformation of the melanocyte to a cutaneous malignant

melanoma, a highly aggressive and increasingly common form of cancer.

4

Melanocyte and Melanoma

The study of the cellular genetics of melanoma is greatly helped by the availability
of established mouse and human melanocyte and melanoma cell lines. The

differences between the melanocytes and melanoma cell lines may provide clues to
understanding the progression from the melanoblast to the melanocyte and from the

melanocyte to malignant melanoma. Normal mouse and human melanocytes are
highly pigmented (9). Melanoma cells are unpigmented or lightly pigmented at low pH,

in which melanocytes by comparison remain pigmented (10). In contrast to malignant
melanoma, normal melanocytes don’t have the ability to grow in an anchorage

independent fashion. Melanoma cells generally will form tumors when implanted into
nude (immunodeficient) mice or syngenic animals.

In terms of the growth

requirements, melanoma cells grow well in a standard culture medium with serum
(125). However, melanocytes require a combination of growth factors, or serum plus

an activator of protein kinase C, often the phorbol ester tumor promoter, tetradecanoyl
phorbol acetate (TPA) (44, 125, 145).

Pigment Cell-specific Transcription

The molecular mechanisms controlling melanocyte differentiation are poorly

understood. The most important characteristic of melanocyte differentiation is

melanogenesis. Precise and coordinated control of gene expression is crucial for
5

normal growth, division and differentiation of cells. The identification of the

transcriptional factors responsible for the regulation of tyrosinase, TRP1 and other
pigment cell-specific genes should eventually enable several important questions to be
answered; in particular, whether factors controlling the expression of the pigmentation

genes also govern melanocyte differentiation.
The microphthalmia (mi) phenotype is associated with the mutant mi locus and
characterized by small non-pigmented eyes, a lack of melanocytes in the skin and

inner ear, a defect of mast cells and osteopetrosis, possibly caused by a dysfunction

of the osteoclasts (52, 57). The coats of mice homozygous for mutant alleles of mi are
white. These mice lack pigmentation due to the absence of melanocytes, unlike albino
mice, which are incapable of producing pigment in structurally normal melanocytes.

Reciprocal melanoblast transplantation experiments showed the cell autonomy of the
defect and aggregation-chimera experiments attest to the inviability of mi/mi

melanoblasts (133). It is hypothesized that mi is required for melanoblast differentiation

and/or proliferation (140). The expression of the mi gene is detected in restricted

tissues, such as melanocytes, heart, mast cells, and the outer layer of the retina (52).

The mi gene encodes a member of the basic helix-loop-helix-leucine zipper (bHLH.zip)
family of transcription factors. The three conserved motifs that constitute this family

are: the basic region, which recognizes a canonical CANNTG DNA-binding sequence,
the HLH motif and the Zip motif. The HLH and Zip motifs participate in protein

dimerization, a prerequisite for DNA binding. Sequence relationships within the
bHLH.Zip proteins show that mi is most related to the transcription factors TFEB,

6

TFEC and TFE3 (7, 52, 57, 158), all of which can form stable heterodimers with mi
and with each other (50). The gene product of the mi gene is predicted to play a major
role in pigment cell specific transcription.
The promoter regions of the mouse and human tyrosinase, TRP-1 and TRP-2

genes have been cloned (11, 60, 61, 79, 100, 132). The cell-type-specific promoter

function of the mouse tyrosinase and TRP-1 genes has been well characterized.

Specifically, the promoter function of the mouse tyrosinase gene was analyzed in
transgenic mice, in which the introduced gene was expressed specifically in skin
melanocytes and retinal pigment cells (8, 73, 142). Kluppel et al. (73) showed that the

270 bp 5’ flanking region of the mouse tyrosinase gene is sufficient to direct its

pigment cell specific transcription in transgenic mice as well as in cultured cells. An 11
bp sequence termed the M box (AGTCATGTGCT) was identified in the mouse TRP-1
promoter (90) and is conserved in TRP-1 and tyrosinase promoters of different species

(61, 90). The M box contains a canonical sequence (CANNTG-E box motif) that is

known to be a binding site for a class of transcription factors with bHLH motifs (67,

101). The products of the mouse mi and human (microphthalmia-associated
transcription factor (MITF) genes (52, 57, 138), bHLH.Zip transcription factors (52,
57), were shown to transactivate the mouse and human tyrosinase as well as TRP-1

promoters (13, 37, 50, 108, 153, 154). Activation requires the presence of an E-box,
corresponding to another CANNTG motif, closer to the start site in human as well as
mouse tyrosinase (13, 154) and is enhanced when the M-box is also part of the
promoter region (13, 37).

7

Role of PKC in Differentiation

Protein Kinase C ( PKC) is a calcium and phospholipid dependent kinase which

has been implicated as a key messenger in cellular signaling (70, 106). PKC is a
family of proteins containing at least 11 isoforms divided into three major groups,

classical, novel and atypical, based on their structure and mode of activation (70). The
classical PKCs (a, 01, 02 and y) require both calcium and phospholipid for activation,

while PKCs belonging to the novel group (8, s, t] and 0) do not require calcium (70,

109). The atypical isotypes (i/X, Q are independent of calcium and diacylglycerol (70).

All isotypes except the atypical ones bind phorbol esters (70). PKC is also the major,

if not the only receptor for phorbol ester tumor promoters (70, 103). Besides activating
PKC, prolonged treatment with phorbol esters can result in down-regulation of the
enzyme (3, 55).

PKC is involved in regulating the growth and differentiation of a variety of cell types
in response to growth factors, neurotransmitters and hormones (36, 91, 126, 136,

148). PKC was originally found to be a kinase which was activated by diacylglycerol
(DAG) and calcium (97). The importance of this enzyme became clear when it was

shown that tumor promoters such as phorbol esters bind to PKC due to their steric
similarity to DAG (123). PKC is the major intracellular receptor for phorbol esters (18,

103). The use of phorbol esters has provided evidence for the potential for PKC to
regulate a plethora of biological events. Several studies have been carried out to

8

define the function of PKC in response to extracellular stimuli. When the cells are

stimulated by phorbol esters, there is an initial activation of PKC. This is followed by
down-regulation and degradation of PKC. It is suggested that the loss of PKC protein
is due to a net increase in proteolysis without a change in the rate of synthesis (155).
The mechanism(s) involved in this process is not clear.

Several lines of evidence suggest that PKC may play a positive role in cell

growth by activating gene transcription. The expression of either c-fos, c-jun or both
genes is induced by PKC (41, 47, 99, 106, 127). These proteins, which form

heterodimers, bind to DNA sequences and activate gene expression (21,45, 102, 124,

129, 130, 146). The DNA sequence to which these dimers bind was originally called
the TPA response element, which is also referred to as the AP1 site (1). This region

was called the TPA response element because it was identified as a sequence that
was responsible for phorbol ester-induced gene expression.
Since each isoform has a distinct tissue specific pattern of expression, it has been
proposed that each member of the PKC family has a unique cellular function. In

addition, it has been proposed that this function may vary depending on the cell type.
PKC ct, p and y are increased during HL60 granulocyte differentiation by RA or DMSO
and also during monocytic differentiation by 1a, 23, dihydroxyvitamin D3 (134). PKCe

has been shown to increase during the HMBA mediated induction of MELC

differentiation (120). The same isoform is the only one which is decreased during
thyrotropin-releasing hormone induction of GH4C1 rat pituitary cells (71).

9
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Transfection of PKCp-ll into rat fibroblasts resulted in an increased rate of cell
growth (53). However, when the p-ll isoform was expressed in HT29 cells, a human

colon cancer cell line, it caused a slowing of cell growth and the transfected cells were

less tumorigenic in nude mice (22). Overexpression of PKCa in NIH 3T3 fibroblasts
resulted in a slightly transformed phenotype (26). Overexpression of PKCa in B16
cells induced a differentiated phenotype (42). Thus it is clear that the effect a particular

PKC species has on cell function depends upon the unique cellular environment found
within that specific cell type.

Retinoids

More than 65 years ago Wolbach et al. (149) established that deficiency of vitamin

A causes squamous metaplasia and keratinization of columnar epithelia of the body.
Since then the crucial role of retinoids in controlling differentiation processes has

become evident from studies conducted in a variety of in vivo and in vitro systems.
Retinoic acid (RA) has been shown to play a critical role in the regulation of growth

and differentiation of many different cell types (88, 89). The role of retinoids in the

control of growth and differentiation of skin epithelium is well documented (23). From

a clinical standpoint, RA has received widespread attention because of its effect in the

treatment of keratinization (111), and pigmentation disorders (17, 115). Most of the in
vitro studies investigating the effects of RA on epithelial differentiation have been

10

performed using epidermal keratinocytes. Differentiation of these cells is efficiently

blocked by addition of vitamin A (33) or RA (4) in the culture medium. Thus, the
modulation of keratinocyte differentiation by topical RA treatment observed in vivo is

successfully reproduced in vitro. However, while the phenotypic control exerted by
retinoids on keratinocytes is well documented, little information is available on the

action of RA on melanocytes (115).
The similarity of the mode of action of retinoids to that of the steroid and thyroid

hormones became evident with the discovery of nuclear receptors for retinoic acid (25,
39, 118). The physiological action of retinoic acid is thought to be mediated by nuclear
retinoic acid receptors (RAR). There are three different subtypes of RAR ( RAR a, p

and y) all of which share structural homology with the superfamily of steroid receptors
(69, 157). Another related class of receptors, the RXR, which specifically bind 9-cis

retinoic acid (86) has been recently described. This class of receptors also consists of
three subtypes ( RXR a, p and y) (94) and can form heterodimers with RAR, as well as

several other members of the steroid super family of receptors (72, 83). These

receptors

act

as

ligand-dependent transcriptional

activators

by

binding

as

heterodimers to specific nucleotide sequences in the response elements of target
genes. The heterodimer of RAR-RXR is thought to be the form which specifically binds

to retinoic acid response elements (RARE) (156). Many genes under direct
trasncriptional control by RA (43). Most of these genes share a common response
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element ( RARE) in their 5' flanking region consisting of a hexanucleotide direct

repeat, usually separated by 5 base pairs (DR-5) (43, 74).

Retinoids, PKC and Melanin Biosynthesis

Phorbol esters have previously been shown to inhibit melanin production in B16
cells and tyrosinase activity and mRNA production in Cloudman 891 melanoma cells
(35, 98). The ability of these compounds to interfere with melanogenesis correlated
with their activity as tumor promoters. Since the major receptor for phorbol esters is

protein kinase C ( PKC) (106, 107, 117), these findings suggest that PKC plays a role

in regulating melanogenesis. There are reports implicating PKC in the effect of UV

irradiation (32, 40) and cytokines (59) on melanin production. It appears that certain
human melanoma cells require PKCp for melanogenesis (116).

Several groups have shown that RA-induced differentiation of various tumor cell

types is accompanied by an increase in PKC expression (37, 93, 104, 126). In B16-F1
mouse melanoma cells, RA induces a 5-8-fold increase in PKCa message and protein
(42, 104, 126). Since this increase in PKCa occurs relatively early during the

differentiation program, Gruber et al. (42) investigated whether overexpression of
PKCa in these cells could mimic some of the effects of RA treatment in these cells.

Overexpression of PKCa was able to induce some of the phenotypic changes (i.e.
decreased monolayer growth rate, elimination of anchorage independent growth and

12

increased melanin production) induced by RA administration (42). Melanin production
is an important differentiation characteristic in these cells. The regulation of this

pathway is complex with many gene products contributing to this process. The role of

retinoids in tyrosinase expression and melanin production is controversial with various
laboratories reporting that they either stimulate, inhibit or have no effect on this

process (19, 28, 31, 42, 112, 113). RA was also found to be a potent inhibitor of

hormone (melanocyte-stimulating hormone M8H) and drug (isobutyl-methylxanthineIBMX, cholera toxin)-induced melanogenesis in mouse melanoma cells (19, 95, 112,

113).

Experimental Objective

The aim of the first part of the study was to determine the role of PKC in the

phorbol ester-induced inhibition of melanogenesis. We found that chronic treatment of

B16 mouse melanoma cells with phorbol dibutyrate (PDBu) down-regulated PKC and

prevented the density-dependent induction of tyrosinase activity, tyrosinase protein

and tyrosinase mRNA. This treatment also decreased the level of TRP-1 protein by
50%, but had no effect on TRP-2 protein level.
The next part of the study focussed on identifying c/s-acting elements in the 5'

flanking region of the mouse tyrosinase gene.

Deletion analysis of the 270 bp 5’

flanking region in B16 cells suggested that a 45 bp region colocalizing with the M-box

region is essential for the transcription of the tyrosinase gene. To investigate these
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findings further, we examined the effect of cell density and PKC activation/depletion on
trancriptional activity and nuclear protein interaction with the M-box region. Our studies

suggest that PKC can regulate promoter function and that one specific DNA-protein

complex correlates with tyrosinase expression. The formation of this complex is
regulated by PKC and antibody studies suggest that one of the components of this
complex is MITF.

Studies on B16 mouse melanoma cells in our laboratory have shown that retinoic
acid (RA) induced differentiation is accompanied by a large increase (5-8 fold) in the
PKCoc protein levels. Gruber et al. (42) have shown that overexpression of PKCa in

these cells stimulated melanin production and increased tyrosinase activity. Studies
also show that depletion of PKC in B16 cells leads to a marked decrease in RAinduced transcriptional activity. This effect was also reflected in a decreased ability of

RARs from PKC-depleted cells to bind to RARE in electrophoretic mobility shift assays

(EMSA) (unpublished observations). In the third part of the study we investigated
whether RA mediates its effect on melanin production through its ability to regulate the

tyrosinase promoter. We found that RA stimulated the expression of a tyrosinase

promoter-luciferase plasmid transfected into B16 cells. EMSA revealed that the M-box
region of the tyrosinase promoter bound both exogenous and endogenous RARs.

14
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Materials and Methods

Cell Culture

B16 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM)
supplemented with 10% heat-inactivated calf serum (Sterile Systems, Logan, UT), 2

mM L-glutamine, 2 mM sodium pyruvate, 50 U/ml penicillin G and 50 pg/ml

streptomycin sulfate. Cells were incubated at 37°C in a 6% CO2/94% air humidified
atmosphere. New cultures were initiated from frozen stock every 6 weeks in order to
prevent phenotypic drift.

Treatment of Cells with Phorbol Esters, 8-bromocyclic AMP and RA

Phorbol, phorbol diacetate and phorbol dibutyrate (PDBu) were obtained from
Sigma Chemical Co., St. Louis, MO. These compounds were dissolved in DMSO

(Dimethyl sulfoxide- Me2SO4) and maintained at -20°C until used. Cells were seeded

at the densities indicated and 24 h later were refed with growth medium containing
DMSO (control) or various concentrations of phorbol esters or RA. At designated

intervals cells were harvested and assayed as described below. When examining the
effect of PDBu on 8-bromocyclic AMP induction of melanogenesis, cells were pre
incubated for 24 h with 1 jiM PDBu or DMSO (control). 8-bromocyclic AMP (0.5 mM,

15

Sigma) + 1-methyl, 3, isobutylxanthine (0.2 mM, Aldrich Chemicals) were then added
in either the absence or continued presence of PDBu. After an additional 24 and 48 h

of incubation, cells were harvested and assayed for tyrosine hydroxylase activity and
the amount of tyrosinase, TRP-1 and TRP-2 proteins by Western blotting as described

below. To measure the effect of PDBu on cell growth, B16 cells were seeded at 2 X

105 cells /100 mm tissue culture dish. After allowing the cells to attach overnight, they
were refed with or without 1 pM PDBu. Control cells received the solvent for PDBu

(DMSO). At 16, 40, 64 and 88 h after this refeeding, triplicate dishes were harvested
and the number of cells enumerated through the use of a hemacytometer.

Tyrosine Hydroxylase Enzyme Activity

Tyrosinase is an unusual enzyme in that it has both tyrosine hydroxylase and
DOPA-oxidase activity. In this study we measured the tyrosine hydroxylase component
by a modification of the method of Pomerantz (119). Cells were washed twice with cold

saline and once with 10 mM soduium phosphate buffer (pH 7.2). After scraping the

cells from the dishes into the phosphate buffer, they were disrupted by sonication for
30 s (in 10 s bursts) at power setting #3 (Heat Systems Sonifier, Plainview, NY). The

reaction mixture consisted of 2 mM L-tyrosine, 2 pCi of L-[3H]tyrosine (40-60 Ci/mmol,
NEN-DuPont, Boston, MA), 10 mM sodium phosphate buffer, pH 6.8 and 50 pM L-

DOPA in a total volume of 400 pl. The reaction was initiated by adding 50 pg of cell
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protein and incubated at 37°C. The reaction was terminated by the addition of 75 pl of

45% TCA (trichloroacetic acid). The resultant precipitate was removed by

centrifugation (4000 X g for 30 min) and the supernatant applied to a Dowex 50

column (0.4 x 8 cm). The void volume plus a 0.5 ml column wash was collected .
Charcoal slurry (500 pl of stock 1.5 g in 20 ml H2O) was then added to this solution

and the samples vortexed intermittently over a 15 min period. The charcoal was

pelleted by centrifugation (4000 X g, 10 min) and a 200 pl aliquot of the supernatant

counted for the production of radioactive H2O. It should be noted that this procedure
measures soluble tyrosine hydroxylase activity i.e., that which is not associated with

melanosomes. However, in the PDBu dose-response experiment (Fig. 1), 1% NP-40
to the extraction buffer was added and obtained similar results.

Assay of PKC enzyme activity

Cells were lysed on ice with 20 mM Tris, pH 7.5, 2 mM EDTA, 0.5 mM EGTA, 1
mM dithiothreitol, 5% Triton X-100, 0.5 mM phenyimethylsulfonyl fluoride and 10

mg/ml aprotinin. Complete cell disruption was further ensured by three consecutive 10sec sonications. The total cell lysate was centrifuged at 12,000 X g for 15 min. The

supernatant was loaded onto a DEAE cellulose anion exchange column (Cellex-D,
Biorad) previously equilibrated with column buffer (20 mM Tris, pH 7.5, 2 mM EDTA,
0.5 mM EGTA, 1 mM dithiothreitol). The column was washed with 15 volumes of

column buffer. The PKC fraction was eluted with 2 volumes of column buffer
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containing 100 mM NaCI and concentrated with a centricon-10 microconcentrator

(Amicon). Protein concentrations of samples were determined by the Pierce BCA
assay. Samples were diluted to equal protein concentrations, and assayed with a
commercially available PKC assay system (Amersham) in the presence and absence

of tetradecanoyl-phorbol-acetate (TPA) and phosphatidyl serine (PS). The degree of
phosphorylation was determined by liquid scintillation counting. Enzyme activity was
calculated from CPM taking into account the specific activity of the radioisotope and

reaction time.

Western Blot Analysis for PKCa, Tyrosinase, TRP-1 and TRP-2

Cells were washed twice with cold PBS and harvested in 250 pl of lysis buffer (10
mM Tris, pH 7.5, 1 mM EDTA, 1% glycerol, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 50

mg/ml aprotinin, 0.5 mM phenylmethylsulfonyl fluoride). Harvested cells were lysed on
ice by sonication as described above. Protein concentrations were determined by the
BCA (Pierce) protein assay system. Crude samples were adjusted to equal protein
concentration in SDS sample buffer, boiled for 4 min, centrifuged in a microfuge for 1

min at high speed and the supernatant proteins electrophoretically separated on 10%
sodium dodecyl sulfate-polyacrylamide gels.

Proteins were electrophoretically

transferred to Hybond-C extra nitrocellulose membrane (Amersham). The membrane

was incubated overnight in blocking solution (5% non-fat dry milk in Tris-buffered
saline (TBS), pH 8.0, containing 0.2% Tween).

18

For detection of PKCoc, a 1:25 dilution of monoclonal anti-PKCa antibody
(Seigagaku, Inc and United Biochemical Corp.) was added for 2 h. For the detection of
the brown locus, albino locus or slaty locus protein, anti-PEP1 (63, 64) at a dilution of

1:3000, anti-PEP7 (65) at a dilution of 1:500, or anti-PEP8 (143), at a dilution of 1:3000

were added to the blots for 2 h respectively. For all the antibodies, the solution was
removed, and the blot washed several times in blocking solution followed by a 1 h

incubation with a 1:3000 dilution of either rabbit anti-mouse IgG conjugated with
horseradish peroxidase (Amersham) for anti-PKC or goat anti-rabbit IgG conjugated
with horseradish peroxidase (Pharmacia) for anti-PEP1, anti-PEP7 or anti-PEP8. The

blots were washed several times in blocking solution and then one final time in

blocking solution lacking milk. Reactive bands were visualized by the enhanced
chemiluminescence method (Amersham). All washes and incubations were performed

at room temperature. All of the immunoblots were quantitated by a computerized laser
scanning densitometer (Molecular Dynamics, CA) and the OD units of the peak area
compared between control and experimental samples.

RNA Isolation and Northern blot Analysis

RNA was isolated by an acid phenol method. Cells were lysed on ice into Solution

A (4M guinidinium isothiocyanate, 25 mM sodium citrate (pH 7.0), 0.5% sarkosyl and
100 mM p-mercaptoethanol) and transferred into 15 ml polypropylene tubes. For every

2 X 106 cells, 1 ml of solution A was used. The following reagents were added
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sequentially with vigorous mixing after each addition: 0.1 volume 2 M sodium acetate
(pH 4.0), 1 volume water-saturated phenol and 0.2 volume of chloroformiisoamyl
alcohol (24:1). The samples were incubated on ice for 15 minutes and then centrifuged
at 12, 000 X g for 30 minutes at 10°C. The supernatant was mixed with an equal

volume of isopropanol and RNA was precipitated for at least 2 hours at -20°C.

Samples were then centrifuged at 12,000 X g for 15 min and the resulting pellet was
dissolved in autoclaved DEPC (Diethyl pyrocarbonate)-treated water. Total RNA in the

resulting mixture was quantitated by measuring absorbance at 260 nm and stored at

-70°C.
RNA samples were electrophoretically separated on a formaldehyde agarose gel

and transferred onto Hybond-N (Amersham) nylon membrane by the downward
displacement method as described in Sambrook et al. (128). A GAPDH cDNA clone
was purchased from the American Type Culture Collection. The cDNA clone for
mouse tyrosinase, TRP-1 and TRP-2 were obtained from Drs. Gunther Schutz

(Germany), Shigeki Shibahara (Japan) and Ian J. Jackson (United Kingdom)

respectively. cDNA fragments were labeled with [32P]dCTP (duPont NEN) using the

multiprime labeling kit from Amersham.
Hybridizations were carrried out in 6 X SSC, 2% SDS and 1 X Denhardt's solution
at 60°C overnight after prehybridization with 20 mg/ml herring sperm DNA at 68°C for

2 h. Blots were sequentially washed in the following conditions until low background
levels were achieved: 0.6 X SSC, 0.1% SDS, 2X15 min at room temperature; 0.6 X
SSC, 0.1% SDS, 2 X 15 min at 42°C; 0.6 X SSC, 0.1% SDS, 2X15 min at 65PC; 0.1
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X 8SC, 0.1% SDS, 15 min at 42°C. Blots were exposed to Kodak X-ray film with an
enhancing screen at -70°C. Autoradiograms were quantitated by densitometer
(Molecular Dynamics, CA).

Construction of Fusion genes

pL1, a promoterless luciferase construct, was described previously (154). The
construct pMTL1 contains the Xbal/BstNI fragment (positions -270 to +6) derived from

the BaLB/c mouse tyrosinase gene cloned upstream from the luciferase gene (154)
and was obtained from Dr. Shigeki Shibahara, Tohoku Univ., Sendai, Japan. The Xbal

and BstNI sites have been converted to BamHI and Xhol sites, respectively, in the

process of construction of the plasmid pMTL1. To construct pMTL2, pMTL.1 was cut
with BamHI and filled in using klenow enzyme, followed by digestion with Hindlll. The

BamHI(Xbal)/Hindlll fragment (positions -270 to -82) was isolated and digested with
RsaL The restriction site, Xbal, shown within the parentheses, represent the original

sequence found in the gene. The resulting Rsal/Hindlll fragment (-127 to -82) was

ligated to the larger fragment of the pMTL1 obtained after the Hindlll digestion in the

earlier step. For pMTL4, pMTL1 was digested with BamHI and Hindlll, filled in using
the Klenow enzyme, and self-ligated. For a construct with an internal deletion,

pMTL1(delta)40, pMTL1 was linearized with Hindlll, filled in using the Klenow enzyme,
and

then

digested

with

BamHI.

The

larger fragment was ligated to the

BamHI(Xbal)/Rsal fragment (positions -270 to -127).
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Transient Transfections

B16 mouse melanoma and NIH3T3 mouse fibroblast cells, seeded at 70%
confluence in a 6-cm dish, were transfected using the calcium phosphate precipitation
method (128). The amounts of the DNA were 7 pg of the fusion gene (pMTL1, 2,

1(delta)40 or 4) and 1.4 pg of (3-galactosidase expression vector pEF-p-gal(154). The
duration of glycerol shock was 2-3 min. Transfected cells were then incubated for 27

h at 37°C and lysed with 100 pl of lysis buffer from the PicaGene luciferase assay
system (Toyo Ink, Inc.). Luciferase activity was measured with a Lumat LB9501
luminometer (Berthold). The activity of P-galactosidase was measured following the

protocol described in Sambrook et. al (128). The luciferase activity was normalized
with the P-galactosidase activity, which was then divided by the value obtained with
pMTL4 and shown as relative luciferase activity.

In some experiments with PDBu and RA-mediated regulation of the mouse

tyrosinase promoter activity, B16 cells were cotransfected with 1.5 pg of pMTL1
together with 0.5 pg of a P-gal expression plasmid (to correct for transfection

efficiency) using the lipofectin procedure according to the manufacturer's protocol

(BRL Life Technologies, MD). After a 5 h incubation at 37°C the DNA-containing
medium was removed and replaced with growth medium and the cells were returned
to the tissue culture incubator for an additional 12 h. The transfected cells were treated
with RA (10 pM) or PDBu (1 pM). For the experiments with PDBu the transfected cells
were then divided into three groups: the first group was treated with DMSO (control),
22
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the second with 1 pM PDBu for 24 h (chronic treatment) and the third group was

treated for the last 1 h of incubation with 1 pM PDBu (acute treatment). All groups
were harvested 48 h after transfection and assayed for luciferase activity using a kit

supplied by Promega (Madison, Wl). Light emissions were detected using a

luminometer (Lumat, LB9501, Berthold Industries). The activity of [3-galactosidase was
measured as described in Sambrook et al. (128). Luciferase activity was normalized to

p-galactosidase activity and the effect of PDBu or RA expressed as a ratio to the
untreated control (set at 100%).

Preparation of nuclear extracts

B16 cells were washed with ice-cold PBS, scraped into PBS and collected by
centrifugation (30 sec 1000 X g) in a microfuge. Cells were disrupted in NP-40 lysis
buffer (10 mM Tris-HCI, pH 7.4, 3 mM CaCI2, 2 mM MgCJ and 1% NP-40). Nuclei

were recovered by centrifugation (5 min at 500 X g) and washed twice with ice-cold

NP-40 lysis buffer. The nuclear pellet was then resuspended in extraction buffer (0.05
M Tris-HCI, pH 7.4, 10% v/v glycerol, 0.01 M monothioglycerol, 0.0001 M Na2EDTA,
0.0001 M PMSF, 0.6 M KCI and 2 pg/ml each of aprotinin, leupeptin and pepstatin),
sonicated 3 X 10 s, incubated for 2-3 h at 4°C and centrifuged at 100,000 X g for 1 h

to obtain a soluble nuclear extract.
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Gel Mobility Shift Assay

Double stranded oligonucleotides corresponding to the wt1 region (Fig. 9A)
containing the M box region of the mouse tyrosinase promoter or AP1 site of the
collagenase promoter (1) or a 33 bp oligonucleotide containing the RARE element,

corresponding to a region in the promoter of the human RAR0 gene (137) were used
as probes in gel shift analysis. The respective double-stranded oligonucleotides were
labeled with [32p]dCTP (3000 Ci/mmol) by end-filling of the 5’ protruding termini with

the Klenow fragment of DNA polymerase I. The labeled oligonucleotides were purified

using a G25-Sephadex column. Gel shift reactions typically contained 10 pg of nuclear
protein from B16 cells han/ested at the indicated times with or without treatment with

PDBu or RA. Gel shift reactions typically contained 10 pg of B16 extracts or sf9 cell
extracts from recombinant hRARal baculovirus-infected cells (1 pg) (122). The
extracts were incubated with 30,000 DPM of labeled oligonucleotides in a reaction

mixture (total volume 25 pl) containing 5 pl of 5X incubation buffer (1 M Tris-HCI, pH
7.5, 0.5 M EDTA, pH 8.0, 3 M NaCI, 3.2 pl [J-mercaptoethanol and 4% glycerol) and 1

pg poly dl-dC for 25 min at room temperature and separated on a 6% polyacrylamide
gel (60:1 acrylamide:bis) in 0.25 X TBE (0.045 M Tris-borate, pH 8.0, 0.0001 M

Na2EDTA) at 20 mA at 23°C. For antibody supershift experiments, 1-2 pg (in 1-2 pl) of
the appropriate antibody was added to the reaction mixture after the initial incubation
of nuclear extract with the radioactive oligonucleotide. This mixture was then incubated

for an additional 45 min before separation in polyacrylamide gels. The antibodies
24
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against c-jun and c-fos were obtained from Santa Cruz Biotechnology Inc., CA. In

experiments with MITF, 3 pl of antiserum specific for MITF (obtained from Dr.
Tachibana, NIDCD, NIH) was used. The identity of shifted bands as RARs was

accomplished by incubating the B16 nuclear extracts or sf9 extracts with 1 pg of

unfractionated serum from the y-HIB polyclonal anti-RAR antibody which cross-reacts
with all the RAR subtypes (122). This mixture was then incubated for an additional 45

min before separation in polyacrylamide gels. After separation, the gels were dried and
autoradiographed to detect protein-DNA complexes.
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PARTI

ROLE OF PKC IN MELANOGENESIS

SUMMARY

Melanogenesis is regulated by a variety of environmental and hormonal factors.
In this part of the study we showed that protein kinase C (PKC) plays a major role in

regulating melanogenesis in B16 mouse melanoma cells. Chronic treatment of B16
cells with PDBu resulted in a concentration-dependent loss of density-dependent

induction of tyrosine hydroxylase activity, which was positively correlated with a
concentration-dependent loss of PKC enzyme activity. Different phorbol derivatives

inhibited tyrosine hydroxylase activity and depleted cellular PKCa in a manner which
reflected their reported tumor promoting activity. Western blotting analysis showed

that PDBu decreased the amount of the brown locus gene product (TRP-1) by 50%

and lowered the amount of the albino locus gene product (tyrosinase) to
undetectable levels. None of the phorbol derivatives affected the level of the slaty

locus protein (TRP-2). Northern analysis suggested that PKCa may regulate the
steady state levels of the respective mRNA of tyrosinase and TRP-1. In addition to
inhibiting the density-dependent increase in tyrosine hydroxylase activity, PDBu

inhibited some, if not all of the 8-bromocyclic AMP-induced increase in tyrosine
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hydroxylase activity. This was accompanied by a decrease in the amount of

tyrosinase protein induced by 8-bromocyclic AMP. Although 8-bromocyclic AMP did
not change the level of TRP-1, it did reverse the decrease in the amount of this

protein induced by PDBu. The amount of TRP-2 was not altered by any of these
agents. These data suggest that PKC regulates melanogenesis primarily by

controlling the constitutive expression of tyrosinase and, to a lesser extent, TRP-1.
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RESULTS

A: PKC and density-dependent melanogenesis

Effect of PDBu on tyrosine hydroxylase activity- During the course of a previous
study (104), we observed that treatment of B16 cells with PDBu prevented the

density-dependent increase in melanin production that normally occurs in these cells.

To investigate this finding, we treated B16 cells with different concentrations of PDBu

for 72 h, then harvested the cells and assayed for tyrosine hydroxylase activity.
Addition of 0.06 pM PDBu resulted in an 80% reduction in tyrosine hydroxylase
activity, while 0.1 pM decreased the activity by 96% when compared to the control
cells (Fig 2 A). Increasing the concentration of PDBu to 1 and 5 pM further
decreased tyrosine hydroxylase activity to a level that was barely above the

background for this enzyme assay.

B16 cells were treated with 1 pM PDBu for different time periods and assayed for
tyrosine hydroxylase activity (Fig 2 B). Control cells exhibited a time-dependent

increase in tyrosine hydroxylase activity that correlated with an increase in cell
density. The greatest rate of increase in enzyme activity occured between 48-56 h,
with an additional increase at 72 h. At all times tested, tyrosine hydroxylase activity

from cells treated with PDBu was barely above the background level for the assay.
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Figure 2
Concentration and time-dependent effect of PDBuon B16 mouse melanoma
tyrosine hydroxylase activity

A. Concentration-dependent effect of phorbol dibutyrate on B16 mouse melanoma
tyrosine hydroxylase activity.
B16 cells were treated for 72 h with the concentrations of phorbol dibutyrate

listed. Control cells received 0.05% DMSO, the solubilization vehicle. At the end of

the incubation, cells were harvested and protein content and tyrosine hydroxylase

activity assayed as described in the methods section. The data are presented as
mean +/- SEM (error bars) of three separate experiments. Samples without apparent

error bars had errors too small to be plotted by the computer graphics program. The

* indicates that the samples were significantly different form control (DMSO) at the
p<0.01 confidence level.

B. Time-dependent change of tyrosine hydroxylase activity in control and phorbol
dibutyrate-treated B16 mouse melanoma cells.

B16 cells were treated with either 0.05% DMSO, or 1 pM phorbol dibutyrate. At
the indicated times, cells were harvested and assayed for protein content and
tyrosine hydroxylase activity as described in the methods section. The data is

presented as the mean +/- SEM (error bars) of three separate experiments.
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Effect of PDBu on growth of B16 melanoma cells- Since the increase in tyrosine

hydroxylase activity is density-dependent, one possible explanation for the effect

of PDBu on inhibition of this enzyme would be an effect on cell proliferation. To test
this possibility we treated B16 cells with 1 pM PDBu and measured its effect on the
growth of these cells. At the same concentration of PDBu which was shown to

drastically inhibit tyrosine hydroxylase activity (Figs 1 & 2), there was little effect on

cell proliferation (Fig 3). Thus the effect of PDBu on inhibition of melanogenesis is
not due to an inhibition of cell growth.

Eelationship between protein kinase C and tyrosinase- PDBu is a potent activator of
PKC (117). In

addition, chronic treatment of cells with PDBu leads to down-

regulation of PKC levels (55, 110). In order to determine whether PDBu was

inhibiting tyrosinase activity by decreasing the amount of tyrosinase protein and
whether this was correlated with changes in PKC enzyme activity, B16 cells were

treated with different concentrations of PDBu for 72 h and cell lysates were tested for
PKC enzyme activity and tyrosinase protein by Western blotting. PDBu induced a

concentration-dependent decrease in tyrosinase protein level which was roughly
correlated with a decrease in PKC enzyme activity (Fig 4A and B). These data

suggest that PKC may be required for expression of tyrosinase and its depletion (by
chronic PDBu treatment) leads to inhibition of melanogenesis.

32

Figure 3

Effect of phorbol dibutyrate on the growth of B16 mouse melanoma cells.

B16 cells were seeded in growth medium at 1 X 105 cells/100 mm tissue culture
dish. After allowing the cells to attach overnight, they were refed with growth medium

containing either 1 pM phorbol dibutyrate or DMSO (solvent for phorbol dibutyrate).
At the indicated times, triplicate dishes from each treatment group were harvested
and cell number determined by hemacytometer counting. The data are presented as
the mean +/- SEM (error bars) of triplicate dishes. In cases where error bars are not

shown, the SEM was too small to be represented in this computer drawn graphic

curve.
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Figure 4
Concentration-dependent changes in PKC enzyme activity and tyrosinase

protein level induced by phorbol dibutyrate in B16 cells.

B16 cells were incubated for 72 h with the indicated concentrations of phorbol
dibutyrate. (A) Cells were harvested and the amount of tyrosinase protein

determined using immunoblotting (50 pg of protein from each sample) with a pep-7

antibody as described in the methods section.

Immuno-reactive bands were

visualized using a chemiluminescence kit purchased from Amersham. Lane 1
contains protein from cells treated with DMSO. The remaining lanes contain
increasing concentrations of phorbol dibutyrate at the amounts indicated in the part

B of this figure. (B) Replicate dishes were harvested and assayed for PKC enzyme
activity as described in Methods. The PKC activity is expressed as a percent of the
control level which was 1.8 pmol 32Pi incorporated into peptide substrate/pg

protein/min. The entire experiment was repeated three times with similar results.
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Effect of phorbol derivatives on PKCa, tyrosinase activity and protein level, TRP-1

and TRP-2 protein levels- In order to obtain further evidence for the involvement of
PKCa in the regulation of tyrosinase, we measured the ability of different phorbol

derivatives to inhibit tyrosine hydroxylase enzyme activity, down-regulate PKCa, and

alter the level of tyrosinase, TRP-1 and TRP-2 proteins. Among the compounds
tested, phorbol treatment resulted in a small but reproducible increase in tyrosine
hydroxylase activity, while both phorbol diacetate and PDBu treatment of cells

consistently decreased tyrosine hydroxylase activity, with the latter compound giving
the greatest inhibition (Fig 5 A).
Next, we examined the ability of these phorbol derivatives to downregulate PKCa

(Fig 5 B). A 72 h treatment with phorbol resulted in a small reduction in PKCa levels.
In contrast, PKCa protein in phorbol diacetate-treated cells was reduced by 83%,

while PDBu treated cells had only 6% of the amount of PKCa found in control cells
(determined by scanning densitometry).

We examined the level of three proteins thought to be involved in the regulation
of melanogenesis, using anti-peptide antibodies which were generously provided by

Dr. Hearing (NIH). TRP-1 is a protein encoded by the brown locus gene. Although it
has some tyrosine hydroxylase and DOPA oxidase activity (66), its exact role in

melanogenesis is yet to be defined. As previously reported (63), B16 cells express a
70-72 kDa protein recognized by TRP-1 specific antibody. We found that phorbol
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Figure 5

The effect of different phorbol derivatives on tyrosine hydroxylase activity,
PKCot levels, TRP-1, tyrosinase and TRP-2 protein levels in B16 mouse
melanoma cells.

B16 mouse melanoma cells were treated for 72 h with phorbol, phorbol diacetate,

phorbol dibutyrate or DMSO (control). All phorbol compounds were used at a

concentration of 1 pM. At the end of the incubation, cells were harvested in
extraction buffer for (A) tyrosine hydroxylase assay, and aliquots were taken for

immunoblot assay of (B) protein kinase Ca (100 pg protein),

(C) TRP-1 (50 pg

protein), (D) tyrosinase (50 pg protein) and (E) TRP-2 (50 pg protein) levels. Details
of tyrosine hydroxylase enzyme assay and immunoblotting are described in the

methods section. In panels B-E; lane 1- control, lane 2- phorbol, lane 3- phorbol
diacetate, lane 4- phorbol dibutyrate. Tyrosine hydroxylase activity is expressed as
the mean +/- SEM (error bars) of three separate experiments.
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consistently increased TRP-1 levels by roughly 2-fold, while PDBu consistently
decreased (40-60% depending on the experiment) TRP-1 levels (Fig 5C). Tyrosinase

is now thought to be encoded by the albino locus gene. Using antibodies specific for
this protein, we detected a 68-70 kDa protein expressed in B16 cells (Fig 5 D).
Shorter exposures of the autoradiograms revealed this protein to be a doublet. As in
the case of TRP-1, treatment with phorbol led to a consistent 3-fold increase in

tyrosinase protein, however in contrast to TRP-1, treatment of B16 cells with PDBu
resulted in the complete loss of immunoreactive tyrosinase protein. TRP-2 maps to
the mouse slaty locus on chromosome 14 and has recently been shown to encode

DOPAchrome tautomerase (143). B16 cells express a protein of 79 kDa which reacts

with peptide-antisera specific for TRP-2 (Fig 5E). In contrast to the effect of the
various phorbol compounds on TRP-1 and tyrosinase, phorbol esters had little effect
on the amount of TRP-2. In some experiments, there was a small increase in TRP-2

(20-37%) in PDBu-treated cells.

Effect of phorbol derivatives on tyrosinase, TRP-1 and TRP-2 mRNA levels- To

determine if phorbol ester-induced changes in tyrosinase, TRP-1 and TRP-2 levels
were reflected in changes in their respective mRNA levels, we extracted total RNA
from cells treated for 72 h with DM80 (control), phorbol, phorbol diacetate or PDBu.
The relative amount of the appropriate mRNA was determined by Northern analysis.
Tyrosinase mRNA levels were reduced approximately 50% by phorbol diacetate and

are not detectable in cells treated with PDBu (Fig 6 A). TRP-1 mRNA levels were
45

Figure 6
The effect of different phorbol derivatives on mRNA level of tyrosinase and

TRP-1

B16 cells were treated for 72 h with DMSO (control), phorbol, phorbol diacetate

and phorbol dibutyrate for 72 h. All phorbol compounds were used at a concentration
of 1 pM. At the end of the incubation cells were harvested and RNA extracted and

purified. 20 pg of RNA from each sample was fractionated on formaldehyde agarose

gels, blotted onto nylon membranes (Amersham) and hybridized with the appropriate
32P-labeled cDNA plasmid as described in the Methods. The blots probed for (A)
tyrosinase and (B) TRP-1 were also assayed for GAPDH mRNA.
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reduced by about 30% with phorbol diacetate treatment of cells, but were reduced by
75% in cells treated with PDBu (Fig 6B). Lastly,TRP-2 mRNA levels were reduced

by about 60% only in cells treated with PDBu (data not shown). Thus the changes in

mRNA for these melanogenic factors induced by phorbol esters roughly parallels
changes in protein levels.

B: PKC and cAMP-induced melanogenesis

Effect of PDBu on 8-bromo-cyclic AMP-induced melanogenesis: All of the
experiments reported thus far, have examined the ability of phorbol esters to inhibit

density-dependent melanogenesis (78). Melanocyte-stimulating hormone (MSH)
increases melanin production in B16 cells even at low cell density, where

“spontaneous” melanogenesis is minimal. MSH stimulates cyclic AMP production
(82, 150), which mediates the action of MSH on melanin production. Therefore, we

examined whether PDBu can also inhibit hormone-induced melanogenesis, using 8bromo-cyclic AMP as a surrogate for MSH-induced increase in cyclic AMP.
B16 cells were preincubated for 24 h with DMSO (control) or 1 jiM PDBu. Each

of these groups were then incubated with 0.5 mM 8-bromo-cyclic AMP + 0.2 mM 1methyl, 3-isobutylxanthine (cyclic AMP phosphodiesterase inhibitor) for an additional
24 or 48 h. Cells harvested at these time points were examined for tyrosine

hydroxylase activity, TRP-1, tyrosinase and TRP-2 protein levels. 8-bromo-cyclic
48
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Figure 7
Effect of 8-bromo-cyclic AMP with or without phorbol dibutyrate on B16 mouse

melanoma tyrosine hydroxylase activity, and TRP-1, tyrosinase and TRP-2

levels.

B16 cells were incubated for 24 h with or without 1 piM PDBu. At this time

replicate dishes were refed with 0.5 mM 8-bromo-cyclic AMP + 0.2 mM 1, methyl, 3
isobutylxanthine in the absence or continued presence of 1 p.M PDBu for an

additional 24 or 48 h. Control cells received DMSO, the solubilization vehicle for

PDBu. At the indicated times cells were harvested and assayed for protein content
and (A) tyrosine hydroxylase activity, (B) TRP-1, (C) tyrosinase and (D) TRP-2

protein levels as described in the text. The tyrosine hydroxylase activity in panel A is
expressed as the mean +/- SEM (error bars) of three separate experiments. Samples

lacking apparent error bars had errors too small to be plotted by the computer

graphics program. In panels B-D; lane 1- 24 h control (DMSO), lane 2- 24 h
PDBu,lane 3- 24 h 8-bromo-cyclic AMP, lane 4- 24 h PDBu + 8-bromo-cyclic AMP,
lane 5- 48 h control (DMSO), lane 6- 48 h PDBu, lane 7- 48 h 8-bromo-cyclic AMP
and lane 8- 48 h PDBu + 8-bromo-cyclic AMP.
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AMP increased tyrosine hydroxylase activity by 2 fold following 24 h of treatment,

and five-fold after 48 h of incubation. PDBu inhibited tyrosine hydroxylase activity
relative to the control cells at both 24 and 48 h of treatment. This phorbol ester also
reduced the degree of the 48 h 8-bromo-cyclic AMP-mediated stimulation of

enzyme activity by 65%, but did not eliminate all of the 8-bromo-cyclic AMP
induced tyrosine hydroxylase activity (Fig 7 A).

We also examined the level of TRP-1, tyrosinase and TRP-2 in the different

treatment groups (Fig 7 B-D). PDBu decreased TRP-1 levels as compared to
control cells at both 24 and 48 h of incubation. 8-bromo-cyclic AMP treatment did
not result in any consistent increase or decrease in TRP-1 levels at either 24 or 48

h of treatment. However, 8-bromo-cyclic AMP did reverse the PDBu inhibition of
TRP-1 expression at both 24 and 48 h treatment times (Fig 7 B; compare lane 2 vs

lane 4 and lane 6 vs lane 8). PDBu also induced a complete loss of tyrosinase
protein following 24 and 48 h of incubation (a faint band was visible at 24 h in the

control cells on the original autoradiogram). Treatment with 8-bromo-cyclic AMP for

24 h resulted in a large increase in tyrosinase protein relative to untreated cells,
while a 48 h treatment with 8-bromo-cyclic AMP gave a further 4-fold increase in
tyrosinase protein levels relative to the control cells. Cells treated with both PDBu
and 8-bromo-cyclic AMP for 24 h still contained very low amounts of tyrosinase

protein. At 48 h of incubation with both agents tyrosinase protein was decreased by
33% compared to cells treated only with 8-bromo-cyclic AMP (Fig 7 C; compare
lanes 7 vs 8). Interestingly, there was a lower MW band that strongly reacted with
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the antiserum and was present in all the samples. Lastly we examined the amount
of TRP-2 (Fig 7D). There was no consistent difference in the level of TRP-2

among the different treatment groups at 24 h of incubation. At 48 h of incubation,

however, there appeared to be a slight decrease in the amount of TRP-2 in all
groups when compared to the 24 h levels.
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DISCUSSION

The regulation of melanogenesis in cultured melanoma cells is complex.
Hormones (82, 150), cell density (78, 147) and pH (80) can all influence melanin

production. We have provided evidence that PKC plays an important role in the

regulation of melanogenesis in B16 mouse melanoma cells. This conclusion is

supported by the loss of tyrosinase activity ( Fig 2 A and B) and melanin production
(visual observation) in cells depleted of PKCa by chronic treatment with PDBu. In
addition, we found that there was a rough correlation between the concentration

dependent ability of PDBu to down-regulate PKC and to decrease tyrosinase
protein levels (Fig 4 A & B). The correlation is not perfect because PKC levels may

have to decrease below a certain critical level before tyrosinase expression is

affected. Also, cells that overexpressed PKCa had higher levels of tyrosinase
activity and produced more melanin (42). The combined weight of these data

strongly suggest that PDBu inhibits tyrosinase via its ability to down-regulate PKC,

rather than by constant stimulation of PKC enzyme activity. We believe that PKCa
is the isoform involved in the regulation of melanogenesis, since it is the only

conventional PKC expressed in B16 cells (126). Although we have detected mRNA

for PKCs and PKCd;, the amount was extremely low and neither form was

increased by retinoic acid (unpublished), which we have shown to induce PKCa
(104) and to stimulate melanogenesis (42). Several other investigators have
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recently reported that PKC may be involved in the stimulation of melanogenesis in
cultured melanoma cells and melanocytes by UV irradiation (32, 40) and cytokines

(59).
Different

phorbol

ester derivatives

have varying

abilities

to

promote

carcinogenesis in the mouse skin model (6). The tumor-promoting ability has
previously been correlated with their ability to inhibit melanogenesis (98). With the
exception of phorbol, the ability of these compounds to down-regulate PKCa

correlated with their effect on inhibition of tyrosine hydroxylase activity and their
reported skin-tumor promoting activity. Similar results were reported by Park et al.

(116) who found that the level of PKC correlated with the degree of melanin

production by melanocytes from various sources.

The mechanism by which phorbol esters, via their ability to down-regulate
PKCa, inhibit tyrosine hydroxylase activity and melanin production does not appear

to involve the increased production or activation of tyrosinase inhibitors (20, 68),
since mixing extracts of control and PDBu-treated cells, gave the predicted additive

enzyme activity (data not shown). This finding is in contrast to that of Park et al.
(116) who reported that PKCp restored tyrosinase activity in human amelanotic

melanoma cells by “activating” the enzyme. They found that tyrosinase protein .
levels were similar in both amelanotic and melanotic cells.

The function of TRP-1 in melanin production is not known. The protein does

have some tyrosine hydroxylase and DOPA oxidase activity, but its specific activity
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is considerably lower than tyrosinase. Thus the residual tyrosine hydroxylase
activity remaining in PDBu-treated cells (Fig 5 A), in spite of complete absence of

tyrosinase protein (Fig 5 D), may be due to TRP-1. The positive effect of phorbol

on tyrosine hydroxylase activity is probably the result of the increased level of both
TRP-1 and tyrosinase protein induced by phorbol.
In 8-bromo-cyclic AMP-treated cells, there was not a strict temporal or

quantitative correlation between tyrosinse hydroxylase activity and tyrosinase
protein levels. These findings may be explained in part by reports that suggest that

the 8-bromo-cyclic AMP-induced increase in tyrosinase activity involves an
increase in the catalytic activity of the enzyme (34, 63), as well as increases in the

synthesis of the protein. In contrast to these findings, Martinez-Lierte et al (95),
reported that M8H and 8-bromo-cyclic AMP decreased dopachrome tautomerase

activity (TRP-2) in B16 cells. Since we failed to detect any decrease in TRP-2

levels, this result suggests that these agents do not decrease dopachrome
tautomerase activity by altering the amount of TRP-2, but rather affect enzyme
activity, either by directly modifying TRP-2 by phosphorylation, or by increasing the

amount or activity of an inhibitory molecule.
Interestingly, 8-bromo-cyclic AMP, which did not alter TRP-1 levels by itself,

reversed the decrease in TRP-1 induced by PDBu. This result suggests that cyclic
AMP may interfere with the ability of PDBu to deplete the cells of PKC. PDBu was
not able to completely inhibit the 8-bromo-cyclic AMP-induced increase in

tyrosinase protein (Fig 7C ). These data correlate with the ability of PDBu to
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reverse some, if not all of the 8-bromo-cyclic AMP-induced increase in tyrosine

hydroxylase enzyme activity (Fig 7 A). Similar results were found by Fuller et al.
(35), in Cloudman S91 melanoma cells. They reported that tetradecanoyl phorbol
acetate (TPA) was not able to completely reverse the stimulation of tyrosine

hydroxylase activity by 8-bromo-cyclic AMP.
Lastly, the presence of a protein that reacted strongly with the antiserum to

tyrosinase (Fig 7C) is intriguing. Two observations argue against this being a non
specific protein. First, it was not present when pre-immune serum was used in

place of the antiserum (data not shown), and second, this protein was only
observed in Western blots using proteins from lower density B16 cells in

experiments examining cyclic AMP-regulated melanogenesis. The same MW

protein was not found where density-dependent melanogenesis was present (Fig
5 D ). The amount of this cross-reacting protein did not correlate with the amount
of tyrosinase, although it still remains a possibility that it could be a proteolytic

product of tyrosinase, which retains the antigenic epitope. The identification of this
protein will require further investigation.
These results strongly suggest that in B16 mouse melanoma cells PKC

regulates melanogenesis by controlling the expression of both tyrosinase and TRP-

1.
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PART II

REGULATION OF MOUSE TYROSINASE PROMOTER FUNCTION

SUMMARY

In the first part of the study we showed that depletion of protein kinase C (PKC)
by chronic treatment of B16 mouse melanoma cells with PDBu prevented cell

density-dependent melanogenesis. This was accompanied by a lack of induction of

tyrosinase protein and mRNA. In this part of the study, we identified a 45 bp region

that is critical for the efficient transcription of the tyrosinase gene by deletion analysis.
The central portion of this region co-localizes with the “M-box” that is conserved in

melanocyte promoters and is flanked by an AP-1-like site. We investigated the effect

of cell density and PDBu on the functional activity of the mouse tyrosinase promoter
by a reporter gene assay and the binding of nuclear proteins from B16 cells. Acute

PDBu treatment of B16 cells transfected with a mouse tyrosinase promoter-luciferase

construct resulted in increased reporter gene activity, while chronic

treatment

inhibited reporter gene activity. Using an oligonucleotide containing the “M-box" and
its flanking residues in electrophoretic mobility shift assays, we found a density

dependent change in the pattern of DNA-protein complexes. One complex was
found to be negatively regulated by chronic treatment. Competition experiments with
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various mutated oligonucleotides demonstrated that both the M-box and flanking

residues are important for nuclear protein binding. The complex whose formation
was inhibited by chronic treatment was shown to contain the basic helix-loop-helix

leucine zipper (bHLH.Zip) protein, microphthalmia-associated transcription factor

(MITF). Acute treatment of B16 cells with PDBu (which stimulated mouse tyrosinase
promoter activity) resulted in the formation of an additional complex containing c-fos.
These results suggest that tyrosinase gene expression is controlled by a number of

different transcription factors. One of these factors, MITF, is likely to be regulated by

PKC.
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RESULTS

A: Transcriptional regulation

Identification of cis-acting elements in the transcriptional regulation of the mouse

tyrosinase promoter: It has been previously found that a 270 bp fragment containing
the mouse tyrosinase promoter is sufficient to confer pigment cell specific expression
of the gene in transgenic mice. To confirm this finding in our cell culture model, we

transfected a plasmid pMTL1 containing the 270 bp promoter region cloned
upstream of the firefly luciferase reporter gene into B16 cells and compared the

reporter activity obtained in non-pigmented NIH 3T3 cells. The fusion gene showed
low levels of activity in NIH 3T3 cells confirming that this region mediates preferential
expression of the tyrosinase gene in pigmented cells (data not shown).
Within the 270 bp promoter region of pMTL1, several potential binding sites for

transcription factors were identified by searching the transcription factor database
(Fig 8 A). This included three CANNTG motifs (nucleotide positions -214 to -209, 104 to -99 and -12 to -7). To identify potential c/s-acting elements responsible for
transcription of the tyrosinase gene, we performed deletion analysis of its promoter

region in B16 mouse melanoma cells (Fig 8 B). In this series of experiments, the

relative luciferase activity is shown as the ratio to the normalized values obtained
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Figure 8
Nucleotide sequence and functional analysis of the -270 bp region of the
mouse tyrosinase promoter.

A. Schematic of the mouse tyrosinase promoter. The coding strand is shown and is

numbered from the transcriptional start site. The two transcriptional start sites are
indicated by asterisks. The CANNTG motifs are open-boxed. The M box region (-107

to -97) is enclosed in a dashed open box. The 5' flanking AP-1 like site is underlined
(dashed).

B. Localization of the c/s-acting elements responsible for transcription of the mouse

tyrosinase gene. The mouse tyrosinase promoter regions used for construction of the

fusion genes are shown to the left. A construct pMTL1(delta)40 contains the internal
deletion of the Rsal/Hindlll fragment (positions -127 to -82). B16 mouse melanoma

cells were cotransfected with each fusion gene and a p-galactosidase construct

(pEF-pgal). Luciferase activity was normalized with p-galactosidase activity (an
internal control), the value of which was then divided by the normalized value
obtained with pMTL4, shown as relative luciferase activity to the right. The data
shown are means +/- standard deviations for three independent experiments.

C. Effect of acute and chronic phorbol dibutyrate treatment on reporter gene activity
in B16 cells transfected with the plasmid pMTL1. B16 cells were co-transfected with

pMTL1 and p-galactosidase expression plasmids as described in Methods.
Luciferase and p-galactosidase activities were determined and after correcting for

transfection efficiency, the effect of PDBu treatment is expressed relative to the
untreated control cells where the amount of luciferase activity is set at 100%.
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with pMTL4. The fusion gene pMTL2, containing the 127 bp promoter region,

showed promoter activity comparable to pMTL1. A construct pMTL1(delta)40, lacking
the Rsal/Hindlll fragment (-127 to -82), gave a significantly lower expression

compared to the values obtained with pMTL1 and pMTL2. The activity of
pMTL1 (delta)40 was similar to that with pMTL4 containing the 82-bp promoter region

(Fig 8 B). The Rsal/Hindlll fragment (-127 to -82) deleted in pMTL1(delta)40 and

pMTL4, contains a 11 bp motif, termed the M-box, AGTCATGTGCT (-107 to -97).

The M-box motif was originally identified in the promoter region of the TRP-1 gene
and is conserved between mouse and human tyrosinase, TRP-1 and TRP-2 genes.

Phorbol ester regulation of tyrosinase promoter activity: The flanking residues of the
M box in the mouse tyrosinase promoter resemble an AP1-like site (underlined -

dashed in Fig 8 A). Based on our previous data that chronic PDBu treatment of

mouse B16 melanoma cells down-regulated PKC and blocked cell density
dependent induction of tyrosinase mRNA, protein and enzyme activity, we tested the

possibility that PKC may regulate mouse tyrosinase promoter activity.

As seen earlier, transient transfection of the plasmid pMTL1 into B16 melanoma

cells resulted in a large amount of luciferase activity compared to the promoterless
plasmid pL1 in which luciferase activity was barely above background levels (data
not shown). Chronic PDBu treatment (24 h) of the transfected cells resulted in
reduction of luciferase activity by more than 50% compared to untreated cells (Fig 8

C). Conversely, acute treatment (1 h) of the transfected cells with PDBu stimulated
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luciferase activity by two fold ( Fig 8 C). Thus it seems likely that PKC regulates

tyrosinase expression by influencing the function of its promoter.

B: Promoter protein-DNA interactions:

Protein complexes associated with the M-box region of the mouse tyrosinase
promoter. C/s-acting elements bind specific nuclear proteins producing a complex

that interacts with the basal transcriptional machinery to stimulate or stabilize
assembly of a pre-initiation complex. We synthesized oligonucleotides spanning the

M-box region to investigate nuclear proteins which bind to this region and whether

their binding was affected by PDBu treatment of the B16 cells. The oligonucleotide
wt1 contains a 21 bp region corresponding to the central region of the 46 bp
Rsal/HindllI fragment (-127 to -82) (Fig 9 A). The oligonucleotide mt1 has a mutation

in the CATGTG motif of the M-box and mt2 has a mutation in the flanking region
leaving the CATGTG motif in the M-box intact (Fig 9 A ).
Using radiolabeled wt1 as a probe, nuclear extracts from highly pigmented B16
cells, were found to produce five major specific DNA-protein complexes (Fig 9 B ). A

100-fold excess of unlabeled wt1 was able to compete all of these complexes, while

the mt1 oligonucleotide at the same concentration did not compete any of the

complexes.
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Figure 9

Effect of PDBu treatment on nuclear protein binding to a region of the mouse

tyrosinase promoter encompassing the M-box and flanking residues.

A. Schematic of the synthetic oligonucleotides wt-1, mt-1 and mt-2 and their relative
position within the mouse tyrosinase promoter. The base changes introduced in the

mt-1 and mt-2 oligonucleotides are denoted by lower case letters.

B. Binding of nuclear protein complexes at the M-box region. The DNA binding
activity of endogenous proteins was analyzed by electrophoretic mobility shift assay
(EMSA). The probe was radiolabeled wt-1 double stranded oligonucleotide,
containing the M-box and its flanking residues from the mouse tyrosinase promoter.
Unlabeled excess of wt-1 and mt-1 oligonucleotides were added in 10, 50 and 100fold excess to check for the specificity of binding of the complexes to the wt-1 DNA.

C. Effect of phorbol dibutyrate on nuclear protein binding and localization of the
putative regions where the complexes may be formed. Nuclear protein binding to the
M-box was compared using extracts (10 pg) from control and B16 cells treated for 72
h with 1 pM phorbol dibutyrate. Unlabeled excess of wt-1, mt-1 and mt-2
oligonucleotides were included at a 200-fold excess in the reaction mixture

containing nuclear proteins from control cells to localize binding regions of the
complexes on the DNA.

D. Effect of chronic treatment of B16 cells with phorbol dibutyrate on PKCcc protein
level. B16 cells were treated with either DMSO or 1 pM phorbol dibutyrate. At the

indicated times cells were harvested as described under “Materials and Methods”. 50
pg of total protein was loaded in all lanes and the levels of PKCcc was determined by

Western blotting using antibodies obtained form Seigagaku Inc.
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A
mouse tyrosinase 5' flanking region
-270
I

-127

I

-80

I

+1

wt1
wtl :

GATCCAAAAGTTAGTCATGTGCTTTGA
gttttcaatcagtacacgaaacttcga

mtl:

GATCCAAAAGTTAGTacTGTGCTTTGA
GTTTTCAATCAtgACACGAAACTTCGA

mt2 :

GATCCAAAAGgTgGTCATGTGCTTTGA
GTTTTCcAcCAGTACACGAAACTTCGA
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Localization of the PKC-mediated regulation of complex formation: Having identified

the protein complexes which bind to this region of the mouse tyrosinase promoter,

we then examined the effect of PDBu treatment (72 h) of B16 cells on complex
formation (Fig 9 C). The major change in PDBu-treated cells, which induces

depletion of PKC (see Fig 9 D), was a complete loss of the slowest mobility complex
(Fig 9 C, complex a). We verified again (see panel B) that unlabeled wt1

oligonucleotide at a 200-fold excess competed all of the complexes, while mt1, also
at a 200-fold excess did not compete any of the complexes. Interestingly, mt2, which

has a mutation in the flanking residues, leaving the CATGTG motif of the M-box
intact (Fig 9 C) was able to compete complexes b and c, but not complex d. This

oligonucleotide weakly competed complexes a and e compared to mt1, with which

there was essentially no competition. It is likely that complexes b and c bind the

CANNTG motif within the M box. Based on these results, we conclude that the other

complexes likely span both the M-box and the 5' flanking residues, since they are not
competed by either mutated oligonucleotide.

D:Cell density is a key regulator of tyrosinase expression:

Cell density dependent changes of tyrosinase, PKCo. and nuclear protein interaction
with the M box region of the tyrosinase promoter: B16 cells seeded at low density do

not produce tyrosinase mRNA or protein (Part I). As the cells reach a certain critical

density, tyrosinase mRNA is induced followed by an increase in tyrosinase activity
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and visible melanin production (Part I). We previously found that there is also a

density-dependent increase in PKCa protein, which roughly correlates with the

increase in melanin production (105). These density dependent changes can be
prevented by chronic treatment with PDBu. In order to determine whether these

changes were reflected in DNA-protein interactions at the M-box region, we prepared
nuclear extracts from B16 cells at different culture periods and analyzed their DNA

interaction by EMSA. We also determined the protein level of tyrosinase and PKCa
in whole cell extracts at the same time points by Western blotting.

Tyrosinase protein increased greatly between 18 and 30 h in culture and was

maximal at 48 h after seeding of the cells (Fig. 10 A). In agreement with our previous
work (126), PKCa was the major PKC isoform expressed in B16 cells. The amount

of PKCa increased dramtically at 48 h in culture and was maintained at this level in
the last time point examined (Fig. 10 B ). Several changes were noted in nuclear

protein binding to the oligonucleotide spanning the M-box region. At the earliest time

point (18 h) only complexes b and c exhibited strong binding (Fig. 10 C). All
remaining time points had five protein complexes (a-e). There was an additional
band a’, which is more easily observed in shorter exposures of the autoradiogram,

seen only in cells at 48 h in culture. The appearance of this DNA-protein complex
correlates with the dramatic increase in PKCa.
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Figure 10
Cell density-dependent changes in tyrosinase protein, PKCa protein and

nuclear protein complexes at the M-box region. Total protein and nuclear
extracts were prepared simultaneously from B16 cells at different times in

culture as described in Methods.

A. Western blotting analysis of tyrosinase protein level. Total protein (25 pg) was
loaded in each lane and tyrosinase protein detected using anti-peptide polyclonal

antibodies (anti-pep7) provided by Dr. V. Hearing, NCI, Bethesda, MD.

B. Western blotting analysis of PKCa protein. Total protein (50 pg) was loaded in

each lane and PKCa protein detected using a monoclonal PKCa specific antibody
from Upstate Biotechnology Corp.

C. EMSA. Nuclear extracts (10 pg) from B16 cells at different times in culture were
incubated with labeled wt-1 oligonucleotide. Specific protein complexes are indicated
on the left of the figure (a-e).
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E. Identification of factors that bind to the M-box region:

Binding of AP-1 transcription factors: In light of our previous results on the role of

PKC and the fact that the flanking residues of the M box resemble an AP-1-like site,
we tested whether the region binds AP-1 transcription factors. One of the

mechanisms by which PKC is thought to mediate its effect is through increasing AP1 transcriptional activity. We tested whether complex a, shown to be absent in cells
chronically treated with PDBu (Fig 9 C), contained either c-jun, c-fos or both proteins.

Nuclear extracts from B16 cells treated with or without PDBu for 72 h were incubated
with wt1 oligonucleotide and antibodies against c-jun or c-fos. We were unable to
detect a super-shift or inhibition of binding of any of the complexes (Fig 11 A). The

flanking residues of the CATGTG motif in the M-box regions overlap an AP-1 site

(Fig 8 A). To test if activation of PKC might increase binding in this region, we
incubated nuclear extracts from B16 cells treated with PDBu for 1 h with a

consensus AP-1 oligonucleotide corresponding to the AP-1 site of the collagenase
promoter (1). Compared to the untreated cells there was a large increase in binding
activity of nuclear proteins from PDBu-treated cells to this site. Inclusion of antibody

to c-fos in the incubation resulted in a decrease in the intensity of the major band and
the appearance of two new slower migrating bands (Fig 11 B-arrows). Addition of c-

jun antiserum to the reaction mixture did not decrease or supershift any of the
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Figure 11
Determination of endogenous c-fos and c-jun binding to wt-1 and consensus

AP-1 oligonucleotides.

A. Nuclear extracts (10 fig) from B16 cells treated with or without 1 jiM PDB (72 h
chronic treatment) were incubated with wt-1 oligonucleotide and antibodies against

c-fos and c-jun (Santa Cruz Biotechnology Inc., CA). 1.5 pig of the antibody in a

volume of 1.5 jil was added to the reaction mixture containing the B16 nuclear

extract and the probe for 45 min. Reaction mixtures were pre-incubated for 20 min
before addition of the antibodies.

B. Nuclear extracts from B16 cells treated with or without 1 jiM PDB (1 h acute

treatment) were incubated with a labeled oligonucleotide corresponding to a
consensus AP-1 site (1) in the collagenase promoter (CGCATGAGTCAGACA with

Bgl-ll and Mlu-I restriction sites on the 5’ end of the upper and lower strand
respectively) and antibodies against c-fos (Santa Cruz Biotechnology Inc., CA) as

described above.

C. Nuclear extracts from B16 cells treated for 1 h with 1 jiM PDBu were incubated

with radiolabeled wt-1 oligonucleotide and antibodies against c-fos and c-jun as

described above.
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complexes (data not shown). Incubation of these same nuclear extracts with the wt1
oligonucleotide resulted in a clearly visible additional band (d’), compared to the five

complexes found in untreated cells, and either a much stronger signal for complex b
or another new complex with slightly slower mobility than complex b (Fig 11 C)

(shorter exposures of the autoradiogram were not able to distinguish between these

two possibilities). Addition of antibodies to c-jun or c-fos decreased the binding of
complexes a, b and e. In addition antibodies to c-fos induced the appearance of two

supershifted bands (Fig 11 C-arrows).

MITF is a component of complex a: Recent studies suggest that MITF, with a

characteristic bHLH.Zip structure may be an important regulator of tyrosinase and
TRP-1 expression (108, 139, 153, 154). The M-box region of the mouse tyrosinase

promoter was shown to bind MITF (154). It was also suggested that the flanking
regions of the M-box may be important for protein binding. We tested the possibility

that complex a, which binds to the region containing the M-box of the mouse
tyrosinase promoter may contain an MITF-like protein. Nuclear extracts from B16

cells were incubated with or without antibody to MITF and

labeled wt1

oligonucleotide. Fig 12 shows that this antibody inhibited the appearance of complex

a and also decreased the intensity of complex e. These effects were likely specific to
the antibody against MITF since antibodies to mouse S-laminin has no effect on any

of the complexes that bound to the wt1 oligonucleotide (data not shown).
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Figure 12

Evidence that MITF is a component of complex a.

Radiolabeled wt-1 oligonucleotide corresponding to the M-box and flanking regions
of the mouse tyrosinase promoter was incubated with or without a 200 fold excess of
wt-1 oligonucleotide or 3 pl of antiserum specific for MITF as described under

“Materials and Methods”.
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DISCUSSION

In the first part of the work, we have presented evidence that chronic PDBu

treatment, through its ability to down-regulate PKC, inhibits expression of tyrosinase
protein and mRNA and induces an amelanotic phenotype (92). In this part of the
study we show that acute PDBu treatment, which activates PKC, stimulates the
tyrosinase promoter when transfected into B16 cells as judged by a reporter gene
assay. Conversely, chronic PDBu treatment, which depletes the cells of PKC, inhibits

the reporter gene activity (Fig 8 C). Thus it seems likely that PKC regulates
tyrosinase expression by influencing the function of its promoter.

A highly conserved region within the 270 bp segment of the tyrosinase promoter
called the M-box is thought to be important for transcription of pigment cell-specific
genes (13, 37, 38, 154). A 45 bp region containing this M-box element was found to
be critical for the efficient transcription of the tyrosinase gene (154). Using a 31 bp

oligonucleotide containing the M-box plus flanking residues, we found that five
specific protein-DNA complexes were formed (Fig 9 B and C) when the
oligonucleotide was incubated with nuclear extracts from B16 mouse melanoma cells

actively producing pigment (as determined by visual observation of the cells and

culture media). In nuclear extracts from B16 cells which were chronically treated with

PDBu, and thus rendered amelanotic (92), the slowest migrating complex was
absent (Fig 9 C). Using oligonucleotides that span this M-box region from the mouse

TRP-1 gene, the mouse tyrosinase and the human tyrosinase, other laboratories
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have found one (37), two (90) or four (13) protein-DNA complexes when these
probes were reacted with nuclear extracts from B16 cells. To investigate this
apparent discrepancy, we examined the intensity and number of protein-DNA

complexes formed with the wt- oligonucletide when nuclear extracts were taken from
cells at different times and densities in culture. The amount of tyrosinase and PKCa

protein present in these cells was dependent on the length of the culture period. We
found that cells which were expressing minimal amounts of tyrosinase had only two
protein complexes associated with the oligonucleotide which spanned the M-box
region. Thus, there are many cell density-dependent changes which occur in B16

melanoma cells and the varying results of other investigators (13, 37, 90) may be

due, at least in part, to the density at which cells were harvested for analysis.
Supporting this conclusion is the recent observation that ectopic expression of MITF
in NIH-3T3 cells results in a cell density-dependent expression of tyrosinase and

TRP-1 (139). Our experiments also revealed that a new DNA-protein complex (a’)
appeared at the time PKCa levels were substantially increased (Fig 10 C). The

possibility that this new complex represented AP-1 transcripton factor, containing c-

jun homodimer or c-jun/c-fos heterodimer was explored.
To address the question of what regions of the 31 bp oligonucleotide (wt1) were

bound by the different complexes, we perfomed competition experiments with

different amounts of wt-1 and two different mutant oligonucleotides (mt-1 and mt-2).
An oligonucleotide mt-1, which contains a mutation in the M-box was not able to

compete any of the five complexes (Fig 9 C). A different oligonucleotide, mt-2, which
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contains a mutation in the 5' flanking residues of the M-box competed two of the five

complexes (b and c) (Fig 9 C). Hence, it is likely that complexes b and c bind to the
CATGTG motif within the M-box. The other complexes likely span both the CATGTG
motif and the 5' flanking residues of the M-box, since they are not competed by two

mutated oligonucleotides. Our results are consistent with the conclusion of Yasumoto
et al. (154) that the flanking residues of the CATGTG motif are important for the

assembly of protein complexes at the M-box region.
In light of our previous results on the role of PKC in the expression of tyrosinase
(Part I) and the fact that the flanking residues of the M-box resemble an AP-1 like site

(Fig 8 A), we determined whether any of the complexes contained AP-I transcription
factor. In contrast to our expectations, none of the complexes were diminished in

intensity or supershifted when nuclear extracts from cells producing melanin were
incubated with anitbodies to c-fos or c-jun (Fig 11 A). Based upon our previous
observation that a new complex (a’) appeared at a time in culture when there was a

large increase in PKC (Fig 10 B and C), we treated the B16 cells briefly (1 h) with
PDBu to activate PKC and determined if this produced complex a’. Nuclear extracts
from these cells were incubated with either wt1 oligonucleotide or a nucleotide

corresponding to the AP-1 site in the collagenase promoter (1). Nuclear extracts from
PDBu-treated cells had a large increase in binding to the authentic AP-1 site and
antibody incubations demonstrated that this complex contained c-fos (Fig 11 B). We

have found that acute PDBu treatment increases c-fos mRNA and protein in B16
cells (Desai and Niles, unpublished data). This increase in c-fos probably accounts
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for the increased binding to the AP-1 site. Antibody against c-jun did not decrease
or supershift any of the bands (data not shown). Since the assay is performed under

non-denaturing conditions, one possibility for this result is that the antigenic site

recognized by the antibody is not available for binding under these conditions.

Using the wt1 oligonucleotide a new complex (d’), was found in nuclear extracts
from PDBu-treated cells. Also, either the intensity of complex b was increased, or a

new complex with somewhat slower mobility than b was formed (Fig 11 C).
Unfortunately, shorter exposures of the autoradiogram did not allow us to distinguish

between these two possibilities. Complexes a and e were decreased in nuclear
extracts incubated with antibodies to either c-jun or c-fos. Additionally, the c-fos

antiserum induced the appearance of two super-shifted bands (Fig 11 C-arrows). It
is not clear if these supershifted bands came from complexes a, b or e. These

results suggest that AP-1 family members may form additional complexes in this
region of the tyrosinase promoter and/or dimerize with other transcription factors to

generate the band pattern found in nuclear extracts from PKC-activated cells. These
changes may account for the increased tyrosinase promoter activity found in B16

cells acutely treated with PDBu (Fig 8 C).
It has been shown that ectopic expression of MITF can transactivate the

tyrosinase promoter and induce melanocytic differentiation (108, 139, 153).
Furthermore, mutations in the mouse mi, and the human MITF result in defective

differentiation of melanocytes (50, 108, 140). Therefore these factors are most likely

key regulators of the pigment cell-specific expression of tyrosinase. We found that
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the presence of the slowest migrating complex (a) which specifically bound to the wt1

oligonucleotide spanning the M-box was absent when nuclear extracts from B16
cells were incubated with an antibody to MITF (Fig 12). This same complex is absent

in cells at low culture density (Fig 10 C) and in cells chronically treated with PDBu

(Fig 9C). Both of these conditions result in amelanotic cells where there is little or no
detectable tyrosinase (92). Thus it is likely that MITF-like protein, which is a
component of this complex, is crucial for tyrosinase expression in B16 melanoma

cells. Also, since down-regulation of PKC inhibits the appearance of this complex, we
speculate that the expression and/or function of this MITF-like protein is regulated by
PKC. Indeed the predicted amino acid sequence of MITF has consensus PKC
phosphorylation sites (52) and it is well established that phosphorylation of

transcription factors plays a major role in their function (15, 56, 58, 87, 114). Future

studies will determine if this MITF-like protein is phosphorylated either directly or
indirectly by PKC and if so, whether this affects its ability to dimerize to other
transcription factors, bind to its response element and/or activate transcription. In
summary, correlation of PKC and tyrosinase expression in melanoma cells suggest

that the tyrosinase promoter is regulated by PKC. The binding of a specific sequence

in the tyrosinase promoter with melanoma cell nuclear protein which contains MITF
is also regulated by PKC.
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PART III

ROLE OF RETINOIC ACID IN TYROSINASE PROMOTER FUNCTION

SUMMARY

We previuosly found that RA increases melanin production in B16 cells.

Experiments were initiated to determine whether RA mediates its effect on melanin
production through its ability to regulate the tyrosinase promoter. The results
demonstrated that RA stimulated the expression of a tyrosinase promoter-reporter

gene construct transfected into B16 cells. Subsequently, we have identified a region
in the 5' flanking region of the mouse tyrosinase gene that binds RARs and functions
as an RARE in its binding characteristics. This RARE site shares homology with a

half-site of a canonical RARE (DR-5) and binds all RAR subtypes. Endogenous

RARs were also found to bind to this site.
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RESULTS

A: Regulation of mouse tyrosinase promoter function by RA:

RA-mediated regulation of tyrosinase promoter activity: RA-induced differentiation of
B16 mouse melanoma cells results in increased melanin production. In light of these
results, we tested the possibility that RA may regulate the mouse tyrosinase

promoter activity. Transient transfection of pMTL1 containing 270 bp of the mouse

tyrosinase promoter upstream of a luciferase reporter gene into B16 mouse

melanoma cells resulted in a strong enhancement of luciferase activity when

compared to the promoterless plasmid pL1 in which the luciferase activity was barely
above the background levels (data not shown). Treatment of the transfected cells
with 10 jiM RA for 24 h stimulated the luciferase activity by 2.5 fold (Fig. 13 A).

Effect of Retinoic acid on protein-DNA complex formation at the M-box region: We

have previously shown that incubation of nuclear extracts from B16 cells that were
producing melanin with a radiolabeled oligonucleotide wt1 (Fig 13 B) resulted in 5

DNA-protein complexes in electrophoretic mobility shift assays. Since RA increased
the expression of a reporter gene driven by a tyrosinase promoter containing the wt1
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Figure 13
3

Effect of RA on mouse tyrosinase promoter function

A. Effect of RA treatment on reporter gene activity in B16 cells transfected with the

plasmid pMTL1. B16 cells were co-transfected with pMTL1 and p-galactosidase

expression plasmids as described in Methods. Luciferase and p-galactosidase
activities were determined and after correcting for transfection efficiency, the effect of
phorbol dibutyrate treatment is expressed relative to the control cells where the

amount of luciferase activity is set at 100%.

B . Effect of RA on nuclear protein binding and determination of endogenous RARs

binding to the M-box region. Nuclear extracts (10 pg) from B16 cells treated with or
without 10 pM RA (48 h) were incubated with wt-1 oligonucleotide and antibodies
against RARs. 1.5 pl of the antiserum RAR y-lll-b that reacts with all RARs (122) was

added to the reaction mixture containing the B16 nuclear extract and the probe for 45

min. Reaction mixtures were pre-incubated for 20 min before addition of the
antibodies.
Lane 1:
Lanes 2, 4:
Lanes 3, 5:
Lanes 4, 5:

labeled wt1 alone
B16 extracts
RA-treated B16 extracts
RAR-y-lllb
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region, we investigated the possibility that one of the complexes contained an RAR.
Nuclear extracts from B16 cells treated with or without 10 pM concentration of RA

(48 h) were incubated with wt1 probe, which contains the M box region and analyzed

for protein-DNA complex formation by EMSA. We found the same profile of
complexes in control and RA-treated cells except that complex a was slightly
reduced in intensity in RA-treated cells compared to the untreated control cells ( Fig

13 B- lanes 2, 3). The nuclear extracts were also incubated with polyclonal antibody

(y-lll-b) that reacts with all the RARs RAR a , p and y) (122). This treatment led to

loss of complex a and a decrease in the intensity of complex d in both RA-treated
and untreated B16 cells (Fig 13 B- lanes 4, 5).

B. The M-box region binds RAR:

Identification of a putative RARE-half site in the flanking region of the M box:
Computer analysis of the 31-bp oligonucleotide (wt1) used in the gel shift

experiments described above revealed a near consensus RARE half-site. To confirm
whether this region binds RARs, we compared the binding of exogenous RAR a, p

and y to the wt-1 oligonucleotide versus their binding to a synthetic p-RARE (DR-5).

Extracts from baculovirus-infected sf9 cells that express RAR a, p or y

were

incubated with radiolabeled p-RARE (Fig 14 A- lanes 1 to 9) or wt-1 (Fig 14 A-lanes

10 to 18) oligonucleotides. The identity of the DNA-protein complexes was confirmed
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Figure 14
The M-box region binds RARs and functions as a RARE in its binding

characteristics

A. Gel shift analysis: The DNA binding activity of RARs to the wt1 oligonucleotide

was analyzed by gel shift assay. As a positive control labeled p-RARE was used and
the identity of the complexes were determined by incubating with antibodies against

RARs.

Lanes 1-9
Lanes 10-18
Lanes 2,10
Lanes 3,11
Lanes 4,12
Lanes 5,13
Lanes 6,14
Lanes 7,15
Lanes 8,16
Lanes 9,17

labeled p-RARE
labeled wt1
sf9 wild-type extract
sf9 RARa extract
sf9 RARp extract
sf9 RARy extract
RARa+RAR y-lll-b
RARp+RAR y-lll-b
RARy+RAR y-lll-b
RARy-lll-b (w/o sf9 extract)

B. wt1 binds RARs as a composite element

Lanes 1-5
Lanes 6-10
Lanes 2-9
Lanes 3,7
Lanes 4,8
Lanes 5,9

labeled p-RARE
labeled wt1
sf9 RARa extract
sf9 RARa extract + wt1 comp.(200 fold)
sf9 RARa extract + mt1 comp.(200 fold)
sf9 RARa extract + mt2 comp.(200 fold)

C. Mutual competition of RARa binding to p-RARE and wt1 oligonucleotides

Lanes 1-5
Lanes 6-10
Lanes 2-9
Lanes 3-5
Lanes 7-9

labeled p-RARE
labeled wt1
sf9 RARa extract
with inc. cone, of wt1 oligonucleotide (10, 50, 100-fold)
with inc. cone, of p-RARE oligonucleotide (10, 50, 100-fold)
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by incubating the extracts and labeled oligonucleotides with antibodies against

RARs. These antibodies were able to “supershift” the specific RAR complexes
binding to the p-RARE as well as the wt1 oligonucleotide (lanes 6 to 8 and 14 to 17).

The wt1 oligonucleotide was able to bind all RAR subtypes (binding of RARy was

seen in longer exposure of the gel to the autoradiogram). Incubation of the RAR

polyclonal antibody with the labeled p-RARE and wt1 show a small amount of non
specific binding ( Fig 14 A- lanes 9 and 17).
In order to determine where RARoc binds within the wt-1 oligonucleotide, we

incubated RARcc with radiolabeled p-RARE and wt-1 oligonucleotides with +/-

equimolar quantities of the oligonucleotides wt-1, mt-1 and mt-2 shown in Fig 9 A.
Neither mt-1 nor mt-2 was able to compete the binding of RARcc to either p-RARE or
wt-1 region (Fig 14 B). At 200-fold excess wt1 oligonucleotide was able to compete

the binding of RARcc to both p-RARE as well as to wt1.

To confirm that the binding of RARs to the wt-1 oligonucleotide was specific,
reciprocal and non-reciprocal competition experiments were performed with
unlabeled excess of p-RARE and wt-1 oligonucleotides. Unlabeled excess of wt-1

and p-RARE was able to compete the binding of RARoc to either p-RARE or wt1 in

non-reciprocal competition experiments (data not shown). As shown in Fig 14 C,
unlabeled excess of p-RARE and wt-1 oligonucleotides were able to compete each
others’ binding of RARcc, to either radiolabeled oligonucleotides.
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DISCUSSION

The cellular effects of RA are mediated by nuclear receptors. RA is thought to

mediate its effect by acting as a ligand and binding to its cognate nuclear receptors
RARs and RXRs (69, 86, 157). These receptors are divided into two groups: the

RARs and RXRs. The latter receptors bind only 9-cis RA, while the former receptors

can bind both 9-cis and all-trans RA . These receptors have been shown to bind to
specific response elements (RAREs-retinoic acid response elements) in the promoter

regions of genes (156). Our laboratory has previously shown that the B16 cells
constitutively express RARcc and RARy and RARp is induced only upon RA

treatment (151). We have also shown that depletion of PKC by chronic PDBu

treatment leads to a marked decrease in the ability of the RARs to bind to p-RARE
(DR-5) (unpublished observations).

A 270 bp promoter region of the mouse tyrosinase gene has been shown to be
sufficient to elicit expression of the tyrosinase gene in vivo as well as in cultured cells

(73). Using the 270 bp upstream region of the tyrosinase promoter in reporter gene

assays, we found that RA increases the promoter activity ( Fig 13 A ). This region
contains an 11 bp motif, termed the “M-box”, that is conserved in promoter regons of
tyrosinase, TRP-1 and TRP-2 genes (). We have shown that the flanking residues

of the CATGTG motif in the M-box plays an important role in the assembly of
transcriptional complexes at this region (Part II). The flanking residues of the

CATGTG motif resemble a half-site of an RARE. Using an oligonucleotide, wt1,

104

spanning the M-box and the flanking residues , we found that this region may be an

RARE in that it is able to bind all RAR subtypes ( Fig 14 A ). We also found that the

binding of RARs to this region is specific in that they are competed by increasing
concentrations of both wt1 and p-RARE (Fig 14 C ).

In addition to increasing melanin production, RA also decreases the monolayer
growth rate in B16 cells. The expression of tyrosinase is regulated as a function of

cell density and therefore, we are currently exploring the effect of RA on the

expression of tyrosinase at the mRNA and protein level, normalizing for the effect
that RA has on the monolayer growth rate. We are also investigating whether retinoid
analogs which have relative specificity for binding and activating individual subtypes

of RARs may indicate which of the RARs regulates tyrosinase expression.
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Mammalian melanin synthesis is a complex process, with many different gene
I

products contributing to the pathway. We have been studying the regulation of

density-dependent melanogenesis in B16 mouse melanoma cells. In this process,

cells seeded at low density do not produce tyrosinase mRNA, protein or melanin

(92). As cells reach a certain critical density, tyrosinase mRNA is expressed, followed
by increased tyrosinase activity and the production of melanin. This process can be

completely inhibited by incubating the cells with phorbol dibutyrate (PDBu). We have

obtained evidence that this inhibition is due to the depletion of PKC. Using different

phorbol derivatives with varying abilities to downregulate PKCcc, we correlated PKC

expression with density dependent induction of tyrosinase and TRP1 (Part I).
Therefore we conclude that PKC is absolutely required for density-dependent

melanogenesis.
The mouse and human tyrosinase genes have been cloned and regions of the

promoter which confer melanocyte specificity identified (the so called M-box).

Linkage of this promoter region to a heterologous gene resulted in the melanocyterestricted expression of the heterologous gene in transgenic mice. We found that

deletion of the M-box region leads to a marked reduction in pigment cell-specific

transcription of the mouse tyrosinase gene. The transcription factor(s) which result in
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melanocyte-specific tyrosinase gene expression are still unknown. Using an
oligonucleotide which spans the M-box region from the tyrosinase promoter, we

found 5 specific protein-DNA complexes in gel shift analysis with nuclear extracts

from B16 cells which were actively expressing tyrosinase (Part II). The slowest
migrating complex was absent when nuclear extracts from PDBu-treated cells ( no

tyrosinase expression) were used in gel shift assay. We also found that antibodies
against MITF and RAR inhibit the formation of this complex (Part II and III).

Additionally, evidence was obtained, that transcription factors directly regulated by

PKC (AP1- jun and fos) may constitute a component of complex(s) formed at the Mbox region (Part II). Thus we conclude that complex a may be critical for efficient
transcription of the mouse tyrosinase gene.

In summary, using RA and PDBu as opposing agents to regulate PKC levels, we
found that tyrosinase expression is controlled by a complex interplay of intracellular

signaling mechanisms, possibly mediated through the frans-acting factors regulating
its transcription. In related studies, showing a cross-talk between signaling pathways

Schule et a). (131) demonstrated that jun-fos and the receptors for RA and vitamin D
recognize a common element in the human osteocalcin gene. It has been shown that

fos can heterodimerize with a bHLH.Zip factor, termed fos-interacting protein (FIP)
(14). The FIP stimulated the transcription of an AP-1 responsive promoter when co-

transfected with c-fos. It would be worthwhile to determine whether MITF can

heterodimerize with c-fos in regulating the transcription of the tyrosinase gene.
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The manner in which PKC regulates tyrosinase gene expression is unknown. It

remains to be seen whether the AP1 factors, MITF or RARs require phosphorylation
for optimal function. All these factors contains putative PKC-phosphorylation sites in
their respective amino acid sequences. We hypothesize that assembly and/or DNA

binding of transcriptional complexes at the M-box region is regulated either directly
or indirectly by PKC. It would be interesting to determine whether MITF, RARs and

AP-1 factors can interact with each other despite the apparent differences in their

structures and whether formation of such complexes is required for tyrosinase
expression.
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REGULATION OF MELANOGENESIS IN B16 MOUSE MELANOMA CELLS BY
PROTEIN KINASE C (PKC)

Harish Mahalingam
ABSTRACT
The pigment cell-specific expression of tyrosinase and TRP1 has been shown

to be important for the production of melanin in pigmented cells. Using a pigmented cell
line, B16 mouse melanoma, we obtained evidence that PKC plays a major role in

regulating melanogenesis. Chronic treatment with phorbol dibutyrate (PDBu) leads to
downregulation of PKC activity and protein levels. This is accompanied by a loss of

pigmentation which is correlated with a 50% reduction and a complete loss of TRP1

and tyrosinase respectively. Similar results were obtained with Northern and Western
blotting indicating that PKC may regulate the steady state levels of these melanogenic
proteins. Deletion analysis of the mouse tyrosinase promoter region showed that a 45

bp region ~100 bp from the transcriptional start site is essential for efficient transcription
of the gene. The central part of this region co-localizes with an 11-bp motif termed the

M-box. This part of the promoter i.e. the M-box is conserved in the promoter regions

of melanocyte-specific genes. Using Retinoic acid (RA) and PDBu as opposing agents
in regulating PKC levels and melanin biosynthesis, we demonstrate a major role for
PKC in transcription of the tyrosinase gene as determined by reporter gene assays. RA

increased and PDBu decreased the transcriptional activity of the pigment cell-specific
tyrosinase promoter. We also found that the assembly of nuclear protein complexes at

the M-box region varies with cell density. One of the complexes was found to be
negatively regulated by chronic PDBu treatment. Antibody-supershift experiments

showed that this PKC-regulated complex may contain microphthalmia-associated

transcription factor (MITF) and retinoic acid receptors (RARs). We conclude that
tyrosinase

gene

expression

is regulated

by a complex

mechanisms, regulated either directly or indirectly by PKC.

interplay

of signaling

